{"rbuWMNwAAAAJ": [["Monica Tafur", 2020, "Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled \u2026"], ["Kartik S Jhaveri", 2020, "Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled \u2026"], ["Ravi J Menezes", 2020, "Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled \u2026"], ["Harry Janssen", 2020, "Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled \u2026"], ["Angela Cheung", 2020, "Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled \u2026"], ["Gideon M Hirschfield", 2020, "Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled \u2026"], ["Jordan Feld", 2020, "Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled \u2026"], ["Willem J Lammers", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Gideon Hirschfield", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Keith D Lindor", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Andrew L Mason", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Annarosa Floreani", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Pier Maria Battezzati", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Xavier Verhelst", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Henk R van Buuren", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Global Primary Biliary Cholangitis Study Group", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Harry LA Janssen", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Jorn C Goet", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["George N Dalekos", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Kalliopi Zachou", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Christophe Corpechot", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Kris V Kowdley", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Bettina E Hansen", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Frederik Nevens", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Pietro Invernizzi", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Maren H Harms", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Marlyn J Mayo", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Nikolaos K Gatselis", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Cyriel Y Ponsioen", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Tony Bruns", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Douglas Thorburn", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Vasiliki Lygoura", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Albert Pares", 2020, "Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis"], ["Adriaan J van der Meer", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Palak J Trivedi", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Carla F Murillo Perez", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Jordan J Feld", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Ana Lleo", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Albert Par\u00e9s", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["GLOBAL PBC Study Group", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Marco Carbone", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Aliya Gulamhusein", 2020, "Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase"], ["Wayel R Zanjir", 2020, "Evaluation of sustained virological response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection"], ["Lisette AP Krassenburg", 2020, "Evaluation of sustained virological response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection"], ["Emily Stotland", 2020, "Evaluation of sustained virological response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection"], ["Firas Georgie", 2020, "Evaluation of sustained virological response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection"], ["Antonio Bertoletti", 2020, "IFN-\u03b1 Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation"], ["Adam J Gehring", 2020, "IFN-\u03b1 Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation"], ["Tom Chu", 2020, "IFN-\u03b1 Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation"], ["June Ann D\u2019Angelo", 2020, "IFN-\u03b1 Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation"], ["Amanda Romney-Vanterpool", 2020, "IFN-\u03b1 Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation"], ["Aman Mehrotra", 2020, "IFN-\u03b1 Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation"], ["Henry LY Chan", 2020, "Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad"], ["Anna SF Lok", 2020, "Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad"], ["Kumar Visvanathan", 2020, "Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad"], ["Kyong-Mi Chang", 2020, "Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad"], ["Marc G Ghany", 2020, "Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad"], ["Junyao Wang", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Norah A Terrault", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Mandana Khalili", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Marc Ghany", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["David Wong", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Abdus S Wahed", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Colina Yim", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Stephen Liu", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Anna S Lok", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["Mayur Brahmania", 2020, "Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America"], ["G Dalekos", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["A Floreani", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["A Pares", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["H Janssen", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["D Thorburn", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["H Van Buuren", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["B Hansen", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["AL Mason", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["D Bernasconi", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["G Hirschfield", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["N Gatselis", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["M Carbone", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["N Cazzagon", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["MJ Mayo", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["SE O\u2019donnell", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["F Nevens", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["PM Battezzati", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["C Corpechot", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["A Reig", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["P Invernizzi", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["K Kowdley", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["T Bruns", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["MG Zuin", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["V Xavier", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["A Gerussi", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["WJ Lammers", 2020, "Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase"], ["Patricia Mendez", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Mark I Avigan", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Anuj Gaggar", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Nathaniel Brown", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Arie Regev", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Ryan T Anderson", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Maria Beumont", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Robert J Fontana", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Bruce Given", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Poonam Mishra", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Veronica Miller", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Cynthia Wat", 2020, "Liver safety assessment in clinical trials of new agents for chronic hepatitis B"], ["Cynthia Levy", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Hamideh Ale Ali", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Kartik Jhaveri", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Liselot W van Erp", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Manasa Narasimman", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Joost PH Drenth", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Aliya F Gulamhusein", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Morven Cunningham", 2020, "Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps"], ["Robert A de Man", 2020, "Nonalcoholic steatohepatitis is associated with liver\u2010related outcomes and all\u2010cause mortality in chronic hepatitis B"], ["Hannah SJ Choi", 2020, "Nonalcoholic steatohepatitis is associated with liver\u2010related outcomes and all\u2010cause mortality in chronic hepatitis B"], ["Keyur Patel", 2020, "Nonalcoholic steatohepatitis is associated with liver\u2010related outcomes and all\u2010cause mortality in chronic hepatitis B"], ["Willem P Brouwer", 2020, "Nonalcoholic steatohepatitis is associated with liver\u2010related outcomes and all\u2010cause mortality in chronic hepatitis B"], ["Wayel MR Zanjir", 2020, "Nonalcoholic steatohepatitis is associated with liver\u2010related outcomes and all\u2010cause mortality in chronic hepatitis B"], ["John Goulis", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Marta Lopez-Gomez", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Kostas Galanis", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Rhea Veelken", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Heng Chi", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Onur Keskin", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Maria Buti", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["George V Papatheodoridis", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Anastasia Kourikou", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Spilios Manolakopoulos", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Vana Sypsa", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Nikolaos Gatselis", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Rafael Esteban", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Florian Van Boemmel", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Alessandro Loglio", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Pietro Lampertico", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["John Vlachogiannakos", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Ramazan Idilman", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Cihan Yurdaydin", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Savvoula Savvidou", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Thomas Berg", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Jose Luis Calleja", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Theodoros Voulgaris", 2020, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B"], ["Mina S Farag", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Andr\u00e9 Boonstra", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Janett Fischer", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Danilo Deichsel", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Margo JH van Campenhout", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Anneke J van Vuuren", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Maria Pfefferkorn", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Florian van B\u00f6mmel", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Peter Ferenci", 2020, "Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B"], ["Nancy Fryzek", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Tiffany Marsh", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Nevitt Morris", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Melissa Weiner", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Regina Hardison", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Imad Nasser", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Linda Stadheim", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Keith Torrey", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Tamara Haller", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Robert P Perrillo", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Alycia Wolfstone", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Manuel Lombardero", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Bilal Nasir", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Orlando Cerocchi", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Kathryn Rushing", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Michael Betts", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Amy Huang", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Doinita Vladutu", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Barbara Lilly", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Rebecca J Torrance", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Abigail Bowen", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Ella Zadorozny", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Jody Mooney", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Philip Lacher", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Danie La", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Anna von Bakonyi", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Sravanthi Kaza", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Paula G Smith", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Ivy Lau", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Richmond Wong", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Lucie Liu", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Sherry R Hall", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["A Sidney Barritt", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Barbara McKenna", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Rosemary A Nagy", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Leslie Huddleston", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Cara Foley", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Adrian M Di Bisceglie", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Ammu Susheela", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["James Keith", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Donna Stoliker", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Seham Noureldin", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Jiayun Chen", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Debra Rowan", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Ashley Shobe", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Averell H Sherker", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Stephanie Kelley", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Sharon Lawlor", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Steven H Belle", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Debra DeMarco Shaw", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Michael K Klebert", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Nata DeVole", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Nifasha Rusibamayila", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Luis J Montaner", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Lisa Kessels", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Frani Averbach", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Jianghe Niu", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Karen Choi", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Danielle Levine", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Rayshawnda Davis", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Alisha C Stahler", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Sheila Bass", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Veronika Podolskaya", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Andrew Pelesko", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Danielle Cardona", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Samuel French", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Claudia Ayala", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Vikki Metheny", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Hsing-Hua Sylvia Lin", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Kelly Oberhelman", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Romuald Kuras", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["John Lake", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Velma Peacock", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Elenita Rivera", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Lupita Cardona-Gonzalez", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Jacki Cerkoski", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Mary E Valiga", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Diana Kaznowski", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Charlotte Hofmann", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Sumodh Kalathil", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Vanessa Haynes-Williams", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Velimir A Luketic", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Daryl Lau", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Asad Javaid", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Qian Zhao", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Michael W Fried", 2020, "HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition"], ["Rozanne C de Veer", 2019, "Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis"], ["K Seng Liem", 2019, "Challenges with stopping long-term nucleos (t) ide analogue therapy in patients with chronic hepatitis B"], ["Kin Seng Liem", 2019, "Limited sustained response after stopping nucleos (t) ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)"], ["David K Wong", 2019, "Limited sustained response after stopping nucleos (t) ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)"], ["Scott Fung", 2019, "Limited sustained response after stopping nucleos (t) ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)"], ["Josephine Wong", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Petros Pechivanoglou", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["William WL Wong", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Yasmin Saeed", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Arcturus Phoon", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Mina Tadrous", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Noha Z Rayad", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Murray D Krahn", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Valeria Rac", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Alex Haines", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Mona Younis", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Joanna M Bielecki", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Aysegul Erman", 2019, "Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"], ["Nicole S Erler", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Louise JM Alferink", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Herold J Metselaar", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Sarwa Darwish Murad", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Robert J de Knegt", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Ewout J Hoorn", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Jessica C Kiefte-de Jong", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Oscar H Franco", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["M Arfan Ikram", 2019, "Diet-Dependent Acid Load\u2014The Missing Link Between an Animal Protein\u2013Rich Diet and Nonalcoholic Fatty Liver Disease?"], ["Kathryn Kitrinos", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Patrick Marcellin", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Belinda Jump", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Robert Flisiak", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["John Flaherty", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Marjoleine Op den Brouw", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Gerald Crans", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Michael Manns", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Kelly Kaita", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Edward Gane", 2019, "Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of \u2026"], ["Tatyana Sandalova", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Xiao Han", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Sebastian Springer", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Renhua Sun", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Ece Canan Sayitoglu", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Benjamin John Josey", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Didem Ozkazanc", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Sara Pellegrino", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Linda Janssen", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Johan Nilvebrant", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Ren\u00e9e Potens", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Anca Apavaloaei", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Per-\u00c5ke Nygren", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Ida Hafstrand", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Adil Doganay Duru", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Adnane Achour", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Anna-Maria Georgoudaki", 2019, "Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin"], ["Qing Xie", 2019, "Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B"], ["Fehmi Tabak", 2019, "Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B"], ["Xun Qi", 2019, "Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B"], ["Liang Chen", 2019, "Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B"], ["Willem Pieter Brouwer", 2019, "Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B"], ["Catherine Jia", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Christopher L Bowlus", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Stephen Caldwell", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Andrew J Muir", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Robert P Myers", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Aldo J Montano\u2010Loza", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Bertus Eksteen", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["John G McHutchison", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Bryan J McColgan", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Nezam H Afdhal", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["G Mani Subramanian", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Mitchell L Shiffman", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Zachary Goodman", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Dora Ding", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Velimir Luketic", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Roger Chapman", 2019, "Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease"], ["Ravi Menezes", 2019, "The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis"], ["Nima Sadoughi", 2019, "The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis"], ["Hooman Hosseini-Nik", 2019, "The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis"], ["Angela C Cheung", 2019, "The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis"], ["Sandra Fischer", 2019, "The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis"], ["Mr Brunetto", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["Nh Afdhal", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["J Liang", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["P Revill", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["T Berg", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["N Brown", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["N Terrault", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["M Cornberg", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["Hly Chan", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["L Vernoux", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["M Beumont-Mauviel", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["S Buchholz", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["S Wang", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["J Petersen", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["M Ghany", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["A Vaillant", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["A Gaggar", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["S Locarnini", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["P Kennedy", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["S Schlottmann", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["B Given", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["Mk Maini", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["Km Chang", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["H Wedemeyer", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["G Dusheiko", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["V Miller", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["Jj Feld", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["U Lopatin", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["P Lampertico", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["E Donaldson", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["J Young", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["T Dickens", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["P Mishra", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["C Wat", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["A Lok", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["M Buti", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["D Apelian", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["C Ferrari", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["G Cloherty", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["G Picchio", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["G Papatheodoridis", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["Hla Janssen", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["F Zoulim", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["M Dandri", 2019, "2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV \u2026"], ["Laurents PS Stassen", 2019, "A wealth of opportunities: an ethnographic study on learning to deliver high-value, cost-conscious care."], ["Erik W Driessen", 2019, "A wealth of opportunities: an ethnographic study on learning to deliver high-value, cost-conscious care."], ["Guusje Bressers", 2019, "A wealth of opportunities: an ethnographic study on learning to deliver high-value, cost-conscious care."], ["Fedde Scheele", 2019, "A wealth of opportunities: an ethnographic study on learning to deliver high-value, cost-conscious care."], ["Renee E Stalmeijer", 2019, "A wealth of opportunities: an ethnographic study on learning to deliver high-value, cost-conscious care."], ["Linda ME Janssen", 2019, "A wealth of opportunities: an ethnographic study on learning to deliver high-value, cost-conscious care."], ["Lorette A Stammen", 2019, "A wealth of opportunities: an ethnographic study on learning to deliver high-value, cost-conscious care."], ["Jorn Goet", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Palak Trivedi", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Adriaan J Van der Meer", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Henk R Van Buuren", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Rozanne de Veer", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Pier M Battezzati", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Cyriel Ponsioen", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Surain Roberts", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["Niels D Goet", 2019, "DERIVATION OF A MACHINE LEARNING MODEL TO PREDICT CLINICAL OUTCOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS"], ["HL Janssen", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["WKW Seto", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Namiki Izumi", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Wan Long Chuang", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Qing Ning", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Y Lim", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Henry Lik Yuen Chan", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Scott K Fung", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Calvin Q Pan", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Kosh Agarwal", 2019, "IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)"], ["Adriaan Van der Meer", 2019, "OPTIMISING TRIAL DESIGN IN LATE-STAGE PRIMARY BILIARY CHOLANGITIS: EVALUATING OPTIONS FOR COMPOSITE CLINICAL ENDPOINT STUDIES"], ["Carla Fiorella Murillo Perez", 2019, "OPTIMISING TRIAL DESIGN IN LATE-STAGE PRIMARY BILIARY CHOLANGITIS: EVALUATING OPTIONS FOR COMPOSITE CLINICAL ENDPOINT STUDIES"], ["Keisuke Ojiro", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Geoffrey S Johnson", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Richard K Sterling", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Daryl T Lau", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["David E Kaplan", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Margaret C Shuhart", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Suzanne Ho", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Jang-June Park", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Michael R Betts", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["William M Lee", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Daniel Traum", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Lewis R Roberts", 2019, "Distinct phenotype and function of circulating V\u00ce\u00b4 1+ and V\u00ce\u00b4 2+ \u00ce\u00b3\u00ce\u00b4 T-cells in acute and chronic hepatitis B."], ["Bettina Hansen", 2019, "Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis"], ["Anna Reig", 2019, "Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis"], ["Maren Harms", 2019, "Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis"], ["George Dalekos", 2019, "Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis"], ["Florian Prechter", 2019, "Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis"], ["Henk Van Buuren", 2019, "Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis"], ["Verhelst Xavier", 2019, "Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis"], ["HL Chan", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Lei Yang", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Heiner Wedemeyer", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Lai Wei", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Jinlin Hou", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Alexander J Thompson", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Jia-Horng Kao", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Harry L Janssen", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Teerha Piratvisuth", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Vedran Pavlovic", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Cheng-Yuan Peng", 2019, "Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data."], ["Ning\u2010Ping Zhang", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Elke Verhey", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["S Guo", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Hendrik W Reesink", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Ji\u2010Yao Wang", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Meral Akdogan", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Krzysztof Simon", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Mircea Diculescu", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Adrian Streinu\u2010Cercel", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["W\u0142odzimierz Mazur", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["ARES Study Group", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Rob J de Knegt", 2019, "Long\u2010term follow\u2010up of patients treated with entecavir and peginterferon add\u2010on therapy for HB eAg\u2010positive chronic hepatitis B infection: ARES long\u2010term follow\u2010up"], ["Zhandong Li", 2019, "Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos (t) ide analogue therapy"], ["Jian Sun", 2019, "Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos (t) ide analogue therapy"], ["Xiaoyong Zhang", 2019, "Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos (t) ide analogue therapy"], ["Jie Peng", 2019, "Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos (t) ide analogue therapy"], ["Tao Yu", 2019, "Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos (t) ide analogue therapy"], ["Matthew Kowgier", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Jean-Michel Pawlotsky", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Christopher R Flud", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Tony Mazzulli", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Andres Duarte-Rojo", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Gary Garber", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Raoel Maan", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Shelly Bolotin", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Christoph Sarrazin", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Marjolein van Tilborg", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Johannes Vermehren", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Gavin A Cloherty", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Benjamin Maasoumy", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Robert J De Knegt", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Fiona Guerra", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Saeed H Al Marzooqi", 2018, "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies"], ["Dalong Sun", 2018, "Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma"], ["Jie Zhang", 2018, "Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma"], ["Tingting Hu", 2018, "Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma"], ["Wenqing Tang", 2018, "Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma"], ["Ruyi Xue", 2018, "Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma"], ["Ling Dong", 2018, "Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma"], ["Firass Georgie", 2018, "Factors Associated with a Low Risk of Hepatocellular Carcinoma (HCC) after Sustained Virological Response (SVR)"], ["Heidy Morales", 2018, "Factors Associated with a Low Risk of Hepatocellular Carcinoma (HCC) after Sustained Virological Response (SVR)"], ["Jason Lau", 2018, "Factors Associated with a Low Risk of Hepatocellular Carcinoma (HCC) after Sustained Virological Response (SVR)"], ["Ioannis Goulis", 2018, "ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil \u2026"], ["Spyros Siakavellas", 2018, "ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil \u2026"], ["Ioannis Vlachogiannakos", 2018, "ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil \u2026"], ["Florian van Bommel", 2018, "ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil \u2026"], ["Kathleen B Schwarz", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Jeffrey H Teckman", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Stewart Cooper", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Simon C Ling", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Jay H Hoofnagle", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Obaid Shakil Shaikh", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Mauricio Lisker-Melman", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Edward Doo", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Philip Rosenthal", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Steve Belle", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Wendy C King", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Norah Terrault", 2018, "Prevalence of Hepatitis B e Antigen Varies By Age, Race and Genotype: Data from a Large North American Cohort of Adults and Children in the Hepatitis B Research Network (HBRN)"], ["Hemant A Shah", 2018, "Limited Sustained Response and Lack of HBsAg Decline after Stopping Long-Term Nucleos (t) Ide Analogue Therapy in Hbeag Negative Patients with Chronic Hepatitis B: Results of a \u2026"], ["Colina K Yim", 2018, "Limited Sustained Response and Lack of HBsAg Decline after Stopping Long-Term Nucleos (t) Ide Analogue Therapy in Hbeag Negative Patients with Chronic Hepatitis B: Results of a \u2026"], ["David KH Wong", 2018, "Limited Sustained Response and Lack of HBsAg Decline after Stopping Long-Term Nucleos (t) Ide Analogue Therapy in Hbeag Negative Patients with Chronic Hepatitis B: Results of a \u2026"], ["Feng Fei Huang", 2018, "Limited Sustained Response and Lack of HBsAg Decline after Stopping Long-Term Nucleos (t) Ide Analogue Therapy in Hbeag Negative Patients with Chronic Hepatitis B: Results of a \u2026"], ["Andre G Uitterlinden", 2018, "The Gut Microbiome and Liver Steatosis in a Western Adult Population: The Rotterdam Study"], ["Arfan Ikram", 2018, "The Gut Microbiome and Liver Steatosis in a Western Adult Population: The Rotterdam Study"], ["Robert Kraaij", 2018, "The Gut Microbiome and Liver Steatosis in a Western Adult Population: The Rotterdam Study"], ["Louise Alferink", 2018, "The Gut Microbiome and Liver Steatosis in a Western Adult Population: The Rotterdam Study"], ["Djawad Radjabzadeh", 2018, "The Gut Microbiome and Liver Steatosis in a Western Adult Population: The Rotterdam Study"], ["Carolina Medina Gomez", 2018, "The Gut Microbiome and Liver Steatosis in a Western Adult Population: The Rotterdam Study"], ["Cedric O De Jong", 2018, "High HBsAg Loss after 13 Years of Follow-up of Interferon-Alpha Treatment for Hbeag-Positive Chronic Hepatitis B: Results from the Elite-B Study"], ["Anneke J Van Vuuren", 2018, "High HBsAg Loss after 13 Years of Follow-up of Interferon-Alpha Treatment for Hbeag-Positive Chronic Hepatitis B: Results from the Elite-B Study"], ["Margo Van Campenhout", 2018, "High HBsAg Loss after 13 Years of Follow-up of Interferon-Alpha Treatment for Hbeag-Positive Chronic Hepatitis B: Results from the Elite-B Study"], ["Andre Boonstra", 2018, "HBV RNA in Serum Is an Early Predictor for HBsAg Loss Following Peg-Interferon Treatment for Patients with Hbeag Positive Chronic Hepatitis B"], ["Mina Farag", 2018, "HBV RNA in Serum Is an Early Predictor for HBsAg Loss Following Peg-Interferon Treatment for Patients with Hbeag Positive Chronic Hepatitis B"], ["Robert A De Man", 2018, "Non-Alcoholic Steatohepatitis Predicts Adverse Liver-Related Outcomes and Death in Chronic Hepatitis B Patients"], ["Alirezah Zahirieh", 2018, "Low Dose Tenofovir Disoproxil Fumarate Improves Kidney Function and Sustains Virologic Suppression in Renally Compromised Chronic Hepatitis B Patients"], ["Jidong Jia", 2018, "Optimizing the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the Sonic-B Study"], ["Stefan Zeuzem", 2018, "Optimizing the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the Sonic-B Study"], ["Yun-Fan Liaw", 2018, "Optimizing the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the Sonic-B Study"], ["Milan J Sonneveld", 2018, "Optimizing the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the Sonic-B Study"], ["BE Hansen", 2018, "Younger age and language barriers are associated with nonadherence to clinical follow\u2010up in hepatitis B treatment"], ["A Japhary", 2018, "Younger age and language barriers are associated with nonadherence to clinical follow\u2010up in hepatitis B treatment"], ["RJ de Knegt", 2018, "Younger age and language barriers are associated with nonadherence to clinical follow\u2010up in hepatitis B treatment"], ["HLA Janssen", 2018, "Younger age and language barriers are associated with nonadherence to clinical follow\u2010up in hepatitis B treatment"], ["RA de Man", 2018, "Younger age and language barriers are associated with nonadherence to clinical follow\u2010up in hepatitis B treatment"], ["Mindie H Nguyen", 2018, "Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes"], ["Issah Younossi", 2018, "Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes"], ["Naoky Tsai", 2018, "Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes"], ["Maria Stepanova", 2018, "Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes"], ["Andrei Racila", 2018, "Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes"], ["Ed Gane", 2018, "Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes"], ["Zobair M Younossi", 2018, "Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes"], ["Stephen Locarnini", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Kathy Jackson", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Peter Revill", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Margaret Littlejohn", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Rosalind Edwards", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Alexander Thompson", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Mani Subramanian", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Darren Wong", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Maria Buti\u2010Ferret", 2018, "ALT flares during nucleotide analogue therapy are associated with HB sAg loss in genotype A HB eAg\u2010positive chronic hepatitis B"], ["Andrzej Horban", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Wai Kay Seto", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Maurizia Brunetto", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Vithika Suri", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Corinna Oberle", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["John F Flaherty", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Ho Bae", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Hyung Joon Kim", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Dzhamal Abdurakhmanov", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Florin A Caruntu", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Shuhei Nishiguchi", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Shuyuan Mo", 2018, "Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use"], ["Enkhnaran Bilegsaikhan", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Xiang-Nan Yu", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Xi-Zhong Shen", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Xiao-Xi Huang", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Ji-Min Zhu", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Hai-Rong Zhu", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Tao-Tao Liu", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Hong-Ying Guo", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Guang-Qi Song", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Xue-Mei Jiang", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Xuan Shi", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Shu-Qiang Weng", 2018, "microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma"], ["Daryl TY Lau", 2018, "Hepatitis B virus infection"], ["Geoffrey M Dusheiko", 2018, "Hepatitis B virus infection"], ["Stephen A Locarnini", 2018, "Hepatitis B virus infection"], ["Ching-Lung Lai", 2018, "Hepatitis B virus infection"], ["Man-Fung Yuen", 2018, "Hepatitis B virus infection"], ["Marion G Peters", 2018, "Hepatitis B virus infection"], ["Ding-Shinn Chen", 2018, "Hepatitis B virus infection"], ["Natalia Lis", 2018, "Cytomegalovirus gp40/m152 uses TMED10 as ER anchor to retain MHC class I"], ["Zeynep Hein", 2018, "Cytomegalovirus gp40/m152 uses TMED10 as ER anchor to retain MHC class I"], ["Swapnil Ghanwat", 2018, "Cytomegalovirus gp40/m152 uses TMED10 as ER anchor to retain MHC class I"], ["Linda Jan\u00dfen", 2018, "Cytomegalovirus gp40/m152 uses TMED10 as ER anchor to retain MHC class I"], ["Venkat Raman Ramnarayan", 2018, "Cytomegalovirus gp40/m152 uses TMED10 as ER anchor to retain MHC class I"], ["V Ravirajan", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["A Marchand-Austin", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["MH Yudin", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["JJ Feld", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["MJ Biondi", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["T Mazzulli", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["L Goneau", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["N Lipton", 2018, "Lack of prenatal HBV and HCV screening and follow-up in Ontario, Canada"], ["RA deMan", 2018, "Histologic predictors of liver-related outcomes and mortality in patients with chronic hepatitis B and non-alcoholic fatty liver disease"], ["HSJ Choi", 2018, "Histologic predictors of liver-related outcomes and mortality in patients with chronic hepatitis B and non-alcoholic fatty liver disease"], ["WP Brouwer", 2018, "Histologic predictors of liver-related outcomes and mortality in patients with chronic hepatitis B and non-alcoholic fatty liver disease"], ["WMR Zanjir", 2018, "Histologic predictors of liver-related outcomes and mortality in patients with chronic hepatitis B and non-alcoholic fatty liver disease"], ["K Patel", 2018, "Histologic predictors of liver-related outcomes and mortality in patients with chronic hepatitis B and non-alcoholic fatty liver disease"], ["J Feld", 2018, "Histologic predictors of liver-related outcomes and mortality in patients with chronic hepatitis B and non-alcoholic fatty liver disease"], ["SM Friedman", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["JV Juan", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["CI Capraru", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["B McCormack", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["AM Vanderhoff", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["HM Jung", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["D Porplycia", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["H Shah", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["K Bates", 2018, "Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area"], ["MJ vanCampenhout", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["F Tabak", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["H Chi", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["L Chen", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["X Qi", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["KS Liem", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["Q Xie", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["NP Zhang", 2018, "Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["S Nishiguchi", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["FA Caruntu", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["E Gane", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["JH Kao", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["M Brunetto", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["HJ Kim", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["D Abdurakhmanov", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["V Suri", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["A Horban", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["H Bae", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["S Mo", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["J Flaherty", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["MB Ferret", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["WK Seto", 2018, "Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use"], ["TD Ying", 2018, "Prevalence and predictors of complementary and alternative medicine use in a migrant-rich chronic hepatitis B population: socio-economics are more important than ethnicity"], ["DK Wong", 2018, "Prevalence and predictors of complementary and alternative medicine use in a migrant-rich chronic hepatitis B population: socio-economics are more important than ethnicity"], ["WR Zanjir", 2018, "Prevalence and predictors of complementary and alternative medicine use in a migrant-rich chronic hepatitis B population: socio-economics are more important than ethnicity"], ["C Yim", 2018, "Prevalence and predictors of complementary and alternative medicine use in a migrant-rich chronic hepatitis B population: socio-economics are more important than ethnicity"], ["A Gehring", 2018, "Enhanced ex vivo detection of HBV-specific T cells"], ["D La", 2018, "Enhanced ex vivo detection of HBV-specific T cells"], ["C Chua", 2018, "Enhanced ex vivo detection of HBV-specific T cells"], ["J Chen", 2018, "Enhanced ex vivo detection of HBV-specific T cells"], ["Onur Kesk\u0131n", 2018, "Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population"], ["Juan De La Revilla", 2018, "Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population"], ["Kostantinos Galanis", 2018, "Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population"], ["Florian van Boemmel", 2018, "Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population"], ["Massimo Colombo", 2018, "Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population"], ["Maria Lehretz", 2018, "Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population"], ["Maurizia Rossana Brunetto", 2018, "Sa1496-1 Year Safety and Efficacy Data in Chronic Hbv Patients with Risk Factors for Tenofovir Disoproxil Fumarate (TDF) after Switching from TDF to Tenofovir Alafenamide (TAF)"], ["Florin Caruntu", 2018, "Sa1496-1 Year Safety and Efficacy Data in Chronic Hbv Patients with Risk Factors for Tenofovir Disoproxil Fumarate (TDF) after Switching from TDF to Tenofovir Alafenamide (TAF)"], ["Wai-Kay Seto", 2018, "Sa1496-1 Year Safety and Efficacy Data in Chronic Hbv Patients with Risk Factors for Tenofovir Disoproxil Fumarate (TDF) after Switching from TDF to Tenofovir Alafenamide (TAF)"], ["H Tiemeier", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["MCGN van den Hout", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["FMS de Vrij", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["SA Kushner", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["M Baghdadi", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["S Darwish Murad", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["JGJ van Rooij", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["WFJ van IJcken", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["RWW Brouwer", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["O Jovanova", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["Najaf Amin", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["Jeffrey Stedehouder", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["CM van Duijn", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["JM Kros", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["Albert Hofman", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["AG Uitterlinden", 2018, "Employed family-based genetic discovery combining linkage analysis and exome sequencing to identify RCL1 as a novel candidate gene for depression, with independent replication \u2026"], ["Muhammad M Mamdani", 2018, "Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study"], ["Diana Martins", 2018, "Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study"], ["Tara Gomes", 2018, "Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study"], ["David N Juurlink", 2018, "Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study"], ["Sandra Knowles", 2018, "Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study"], ["Andrew Mason", 2018, "Milder disease stage in patients with primary biliary cholangitis over a 44\u2010year period: a changing natural history"], ["Nicholas F LaRusso", 2018, "Milder disease stage in patients with primary biliary cholangitis over a 44\u2010year period: a changing natural history"], ["Raoul Poupon", 2018, "Milder disease stage in patients with primary biliary cholangitis over a 44\u2010year period: a changing natural history"], ["FMS De Vrij", 2018, "A rare missense variant in RCL1 segregates with depression in extended families"], ["J Stedehouder", 2018, "A rare missense variant in RCL1 segregates with depression in extended families"], ["M Subramanian", 2018, "DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment"], ["JG Mchutchison", 2018, "DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment"], ["S Kottilil", 2018, "DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment"], ["Y Gindin", 2018, "DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment"], ["Z Jiang", 2018, "DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment"], ["A Van der Meer", 2018, "The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy"], ["F Georgie", 2018, "The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy"], ["O Cerocchi", 2018, "The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy"], ["J Lau", 2018, "The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy"], ["L Krassenburg", 2018, "The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy"], ["F van B\u00f6mmel", 2018, "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B"], ["Y Cakaloglu", 2018, "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B"], ["P Ferenci", 2018, "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B"], ["M Farag", 2018, "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B"], ["V Rijckborst", 2018, "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B"], ["MV Campenhout", 2018, "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B"], ["HA Shah", 2018, "Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B"], ["S Liem", 2018, "Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B"], ["S Fung", 2018, "Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B"], ["A Zahirieh", 2018, "Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B"], ["D Wong", 2018, "Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B"], ["R de Knegt", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["O Franco", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["SD Murad", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["H Metselaar", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["J Schoufour", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["L Alferink", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["N Erler", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["K Trajanoska", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["F Rivadeneira", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["A Ikram", 2018, "Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study"], ["D Ding", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["C Levy", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["A Montano-Loza", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["C Bowlus", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["S Caldwell", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["R Myers", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["B Eksteen", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["A Muir", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["V Luketic", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["RWG Chapman", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["M Shiffman", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["Z Goodman", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["MP Manns", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["B Mccolgan", 2018, "Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis \u2026"], ["N-P Zhang", 2018, "Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["C Liang", 2018, "Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["T Fehmi", 2018, "Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B"], ["K Munawar", 2018, "Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity"], ["E Stotland", 2018, "Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity"], ["A Gulamhusein", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["KV Kowdley", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["CFM Perez", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["A Cheung", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["P Trivedi", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["K Zachou", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["N Larusso", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["K Lindor", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["C Ponsioen", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["R Poupon", 2018, "Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis"], ["M Harms", 2018, "Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis\u2013even in patients without biochemical improvements"], ["J-H Kao", 2018, "Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use"], ["JF Flaherty", 2018, "Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use"], ["W-K Seto", 2018, "Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use"], ["H Andrzej", 2018, "Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use"], ["D Kaznowski", 2018, "Spontaneous clearance of HCV RNA after documented relapse following DAA-therapy: A case-control study"], ["M Kuczynski", 2018, "Spontaneous clearance of HCV RNA after documented relapse following DAA-therapy: A case-control study"], ["H Kuriry", 2018, "Spontaneous clearance of HCV RNA after documented relapse following DAA-therapy: A case-control study"], ["SP Cleary", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["CC Bell", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["B Sander", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["HF Zangneh", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["WW Wong", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["K Mumtaz", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["M Kowgier", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["KK Chan", 2018, "Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response"], ["M Biondi", 2018, "Low rates of prenatal testing for hepatitis B and C infections in Ontario, Canada"], ["K Sahdra", 2018, "Low rates of prenatal testing for hepatitis B and C infections in Ontario, Canada"], ["Audrey H Lau", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Manoj Sharma", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Ki Tae Yoon", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Neeru Bhardwaj", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Young-Suk Lim", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Wan\u2013Long Chuang", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Mustafa Kemal \u00c7elen", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Norihiro Furusyo", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Edward J Gane", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Andrea L Cathcart", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["GS-US-320-0108 Investigators", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Lanjia Lin", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Sang Hoon Ahn", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Huy Trinh", 2018, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection"], ["Jian Wu", 2018, "Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence"], ["Ying Fang", 2018, "Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence"], ["Xi Zhong Shen", 2018, "Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence"], ["Juan He", 2018, "Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence"], ["Anh-Hoa Nguyen", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Yoon Jun Kim", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Benedetta Massetto", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Eric M Yoshida", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Jacky Woo", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Adarsh Joshi", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Naoky CS Tsai", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Carlo Ferrari", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["Maurizia R Brunetto", 2018, "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"], ["M van Tilborg", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["J Vermehren", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["C Sarrazin", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["J Pawlotsky", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["R Maan", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["A Duarte-Rojo", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["S Almarzooqi", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["B Maasoumy", 2018, "A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?"], ["M Gamil", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["M Brahmania", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["MS Sulkowski", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["V Cherepanov", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["SA MacParland", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["R Harrigan", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["MA Ostrowski", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["S Yoon", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["C Capraru", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["A Rahman", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["L Vijgen", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["M Beumont", 2018, "A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NA\u00cfVE PATIENTS"], ["M Kelley", 2018, "A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE"], ["O Ahmed", 2018, "A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE"], ["M Sherman", 2018, "A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE"], ["E Renner", 2018, "A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE"], ["R Beecroft", 2018, "A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE"], ["K Khalili", 2018, "A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE"], ["Global PBC Study Group", 2018, "Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome"], ["Fergus Couch", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Huong D Meeks", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Setareh Moghadasi", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Rob B van der Luijt", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Christie J Van Asperen", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Erik Teugels", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Anne-Marie Gerdes", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Nicolas Janin", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["David E Goldgar", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Emily J Hallberg", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Norbert Arnold", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Kathleen BM Claes", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Sandrine M Caputo", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Amanda Ewart Toland", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Torben A Kruse", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Hans Ehrencrona", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Arjen R Mensenkamp", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Thomas Van Overeem Hansen", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Linda AM Janssen", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Christoph Engel", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Margriet J Coll\u00e9e", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Inge S\u00f8kilde Pedersen", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Andrea Gehrig", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Valeria Viassolo", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Mads Thomassen", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Encarna G\u00f3mez Garc\u00eda", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Ans MW Van Den Ouweland", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Amanda B Spurdle", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Muriel A Adank", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Barbara Wappenschmidt", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Maaike PG Vreeswijk", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Jan C Oosterwijk", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Kathy Tucker", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Uffe Birk Jensen", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["\u00c5ke Borg", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Marinus J Blok", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Peter Devilee", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Diana E Eccles", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Bent Ejlertsen", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["Ylva Paulsson-Karlsson", 2018, "The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA \u2026"], ["EW Blom", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["MWG Ruijs", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["JC Oosterwijk", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["MPG Vreeswijk", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["TAM van Os", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["NH Dijkstra", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["MGEM Ausems", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["CJ van Asperen", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["CHM van Deurzen", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["CP Schroder", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["M Rodr\u00edguez\u2010Girondo", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["JT Wijnen", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["WAG van Zelst\u2010Stams", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["RA Oldenburg", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["V Grundeken", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["MA Adank", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["JWM Martens", 2018, "Performance of BRCA1/2 mutation prediction models in male breast cancer patients"], ["Jeannie Callum", 2018, "Hematologic Challenges in ICU Patients with Liver Disease and Gastrointestinal Hemorrhage"], ["Walter Dzik", 2018, "Hematologic Challenges in ICU Patients with Liver Disease and Gastrointestinal Hemorrhage"], ["Owen Tsang", 2018, "Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B"], ["Hiroshi Yatsuhashi", 2018, "Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B"], ["Tatjana Stepanova", 2018, "Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B"], ["Wai Kay Walter Seto", 2018, "Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B"], ["Harry La Janssen", 2018, "O-048: Safety and Efficacy at 1-Year after Switching from TDF to TAF in CHB Patients with Risk Factors for TDF Use"], ["Jia-horng Kao", 2018, "O-048: Safety and Efficacy at 1-Year after Switching from TDF to TAF in CHB Patients with Risk Factors for TDF Use"], ["Maurizia Brunet-to", 2018, "O-048: Safety and Efficacy at 1-Year after Switching from TDF to TAF in CHB Patients with Risk Factors for TDF Use"], ["Byoung Kuk Jang", 2018, "O-048: Safety and Efficacy at 1-Year after Switching from TDF to TAF in CHB Patients with Risk Factors for TDF Use"], ["H Van Vlierberghe", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["T Serste", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["S Bourgeois", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["S Francque", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["D Sprengers", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["C Moreno", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["S Van Hees", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["T Vanwolleghem", 2018, "Sustained off-treatment response is associated with HBsAg loss following Nucleos (t) ide Analogue induced HBeAg seroconversion"], ["KD Lindor", 2018, "Ursodeoxycholic acid is associated with an improved liver transplantation-free survival in primary biliary cholangitis"], ["MH Harms", 2018, "Ursodeoxycholic acid is associated with an improved liver transplantation-free survival in primary biliary cholangitis"], ["CY Ponsioen", 2018, "Ursodeoxycholic acid is associated with an improved liver transplantation-free survival in primary biliary cholangitis"], ["GM Hirschfield", 2018, "Ursodeoxycholic acid is associated with an improved liver transplantation-free survival in primary biliary cholangitis"], ["A Mason", 2018, "Ursodeoxycholic acid is associated with an improved liver transplantation-free survival in primary biliary cholangitis"], ["AJ van derMeer", 2018, "Ursodeoxycholic acid is associated with an improved liver transplantation-free survival in primary biliary cholangitis"], ["HR van Buuren", 2018, "Ursodeoxycholic acid is associated with an improved liver transplantation-free survival in primary biliary cholangitis"], ["Ren-Zheng Huang", 2018, "Microarray expression profiling of microRNAs reveals potential biomarkers for hepatocellular carcinoma"], ["J Goet", 2018, "Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis\u2013the Global PBC Study Group"], ["Milan Sonneveld", 2018, "Treatment of hepatitis B"], ["Jurrien Reijnders", 2018, "Treatment of hepatitis B"], ["K Jackson", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["P Marcellin", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["A Thompson", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["M Littlejohn", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["G Rosenberg", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["L Yuen", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["H Mason", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["J Bayliss", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["K Kitrinos", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["PA Revill", 2018, "HB eAg levels at week 24 predict response to 8 years of tenofovir in HB eAg\u2010positive chronic hepatitis B patients"], ["Korosh Khalili", 2018, "Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis"], ["E Jenny Heathcote", 2018, "Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis"], ["Hemant Shah", 2018, "Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis"], ["Morris Sherman", 2018, "Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis"], ["Suraj A Sharma", 2018, "Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis"], ["Zachary Liederman", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Andrew D Zelenetz", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Lisa K Hicks", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Anna Lok", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Kelvin Chan", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Jessica Hwang", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Neil Berinstein", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Patricia Leung", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Michael Crump", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["C Tom Kouroukis", 2017, "HBV Care Map for Patients Receiving Anti-CD20 Therapy"], ["Fabien Zoulim", 2017, "How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?"], ["Neil Rajoriya", 2017, "How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?"], ["Christophe Combet", 2017, "How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?"], ["Lonneke Jansen", 2017, "HB sAg loss after peginterferon\u2010nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow\u2010up"], ["HW Reesink", 2017, "HB sAg loss after peginterferon\u2010nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow\u2010up"], ["MH Van Der Ree", 2017, "HB sAg loss after peginterferon\u2010nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow\u2010up"], ["R Bart Takkenberg", 2017, "HB sAg loss after peginterferon\u2010nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow\u2010up"], ["F Stelma", 2017, "HB sAg loss after peginterferon\u2010nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow\u2010up"], ["HL Zaaijer", 2017, "HB sAg loss after peginterferon\u2010nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow\u2010up"], ["MW Peters", 2017, "HB sAg loss after peginterferon\u2010nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow\u2010up"], ["Eberhard L Renner", 2017, "Wait time for curative intent radio frequency ablation is associated with increased mortality in patients with early stage hepatocellular carcinoma"], ["Melissa Kelley", 2017, "Wait time for curative intent radio frequency ablation is associated with increased mortality in patients with early stage hepatocellular carcinoma"], ["Rob Beecroft", 2017, "Wait time for curative intent radio frequency ablation is associated with increased mortality in patients with early stage hepatocellular carcinoma"], ["Osman Ahmed", 2017, "Wait time for curative intent radio frequency ablation is associated with increased mortality in patients with early stage hepatocellular carcinoma"], ["Donna Evon", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Stewart L Cooper", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Abdus Wahed", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Mauricio \u2010Melman", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Margaret Shuhart", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Coleman I Smith", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Yona Cloonan", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Chia C Wang", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Jang\u2010June Park", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["David Kleiner", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Tram T Tran", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["T Jake Liang", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Hepatitis B Research Network (HBRN)", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Son Do", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Lilia Ganova\u2010Raeva", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Steven\u2010Huy B Han", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Robert Perrillo", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Lili Punkova", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Daryl T\u2010Y Lau", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Raymond T Chung", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Joshua Juan", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Kyong\u2010Mi Chang", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Jenny Heathcote", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["LA Janssen", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["H\u2010HS Lin", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Robert C Carithers", 2017, "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment"], ["Elisabeth PC Plompen", 2017, "Prediction of long\u2010term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE\u2010B score"], ["Suzan D Pas", 2017, "Prediction of long\u2010term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE\u2010B score"], ["Rob A de Man", 2017, "Prediction of long\u2010term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE\u2010B score"], ["AJP van der Meer", 2017, "Prediction of long\u2010term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE\u2010B score"], ["Fiebo JW ten Kate", 2017, "Prediction of long\u2010term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE\u2010B score"], ["Janke Schinkel", 2017, "NK cells in self\u2010limited HCV infection exhibit a more extensively differentiated, but not memory\u2010like, repertoire"], ["RA De Groen", 2017, "NK cells in self\u2010limited HCV infection exhibit a more extensively differentiated, but not memory\u2010like, repertoire"], ["NA Kootstra", 2017, "NK cells in self\u2010limited HCV infection exhibit a more extensively differentiated, but not memory\u2010like, repertoire"], ["Gertine van Oord", 2017, "NK cells in self\u2010limited HCV infection exhibit a more extensively differentiated, but not memory\u2010like, repertoire"], ["Mariia Prins", 2017, "NK cells in self\u2010limited HCV infection exhibit a more extensively differentiated, but not memory\u2010like, repertoire"], ["ZMA Groothuismink", 2017, "NK cells in self\u2010limited HCV infection exhibit a more extensively differentiated, but not memory\u2010like, repertoire"], ["Danni Colledge", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Gillian Rosenberg", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Kathryn M Kitrinos", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Kathleen Jackson", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Lilly Yuen", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Peter A Revill", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Vitina Sozzi", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Julianne Bayliss", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Rachel Hammond", 2017, "Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive \u2026"], ["Wayel Zanjir", 2017, "Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B"], ["Thomas Ying", 2017, "Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B"], ["Naoky C Tsai", 2017, "The combination of entecavir and peginterferon alfa-2a in HBeAg-positive immune tolerant (IT) adults with chronic hepatitis B virus (HBV) infection: Results of the HBRN IT Trial"], ["Kali Zhou", 2017, "Rate and Predictors of Phase Transition Among North American Adults with HbeAg-Negative Chronic Hepatitis B and Low Level Viremia: a Hepatitis B Research Network (HBRN) Study"], ["Sharon Hunt", 2017, "The impact of treatment of chronic hepatitis B (CHB) on patient-reported outcomes (PROs)"], ["Robert Perillo", 2017, "ALT Flares are Associated with Increased Rates of HBeAg Seroconversion and HBV DNA Decline in Chronic Hepatitis B Infection: A Prospective Cohort Study from the Hepatitis B \u2026"], ["Adrian Bisceglie", 2017, "ALT Flares are Associated with Increased Rates of HBeAg Seroconversion and HBV DNA Decline in Chronic Hepatitis B Infection: A Prospective Cohort Study from the Hepatitis B \u2026"], ["Yona K Cloonan", 2017, "High Prevalence of Naturally Occurring HBV Variants Across HBV Phenotypes and Genotypes in Racially Diverse Patients with Chronic Hepatitis B in the United States and Canada"], ["Lilia Ganova-Raeva", 2017, "High Prevalence of Naturally Occurring HBV Variants Across HBV Phenotypes and Genotypes in Racially Diverse Patients with Chronic Hepatitis B in the United States and Canada"], ["Obaid S Shaikh", 2017, "High Prevalence of Naturally Occurring HBV Variants Across HBV Phenotypes and Genotypes in Racially Diverse Patients with Chronic Hepatitis B in the United States and Canada"], ["Jenny C Yang", 2017, "Evaluation of Factors Associated with Differences in ALT Normalization between Virally Suppressed TAF-and TDF-treated CHB Patients"], ["Hongyuan Wang", 2017, "Evaluation of Factors Associated with Differences in ALT Normalization between Virally Suppressed TAF-and TDF-treated CHB Patients"], ["Huy N Trinh", 2017, "Evaluation of Factors Associated with Differences in ALT Normalization between Virally Suppressed TAF-and TDF-treated CHB Patients"], ["Chi-Yi Chen", 2017, "Evaluation of Factors Associated with Differences in ALT Normalization between Virally Suppressed TAF-and TDF-treated CHB Patients"], ["Shalimar", 2017, "Evaluation of Factors Associated with Differences in ALT Normalization between Virally Suppressed TAF-and TDF-treated CHB Patients"], ["Owen Tak Yin Tsang", 2017, "Evaluation of Factors Associated with Differences in ALT Normalization between Virally Suppressed TAF-and TDF-treated CHB Patients"], ["Henry Lik-Yuen Chan", 2017, "Serum HBsAg levels predict the severity of liver fibrosis among HBeAg-positive patients across all major HBV genotypes and among patients with low ALT levels: results from the \u2026"], ["Nicole Erler", 2017, "High dietary acid load is associated with nonalcoholic fatty liver disease (NAFLD) in a large population-based study: The Rotterdam Study"], ["Josje D Schoufour", 2017, "High dietary acid load is associated with nonalcoholic fatty liver disease (NAFLD) in a large population-based study: The Rotterdam Study"], ["Mohammad A Ikram", 2017, "High dietary acid load is associated with nonalcoholic fatty liver disease (NAFLD) in a large population-based study: The Rotterdam Study"], ["Louise J Alferink", 2017, "High dietary acid load is associated with nonalcoholic fatty liver disease (NAFLD) in a large population-based study: The Rotterdam Study"], ["Thierry Verbinnen", 2017, "Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Clearance and could be a Valuable Endpoint for Early Development HBV Trials"], ["Leen Slaets", 2017, "Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Clearance and could be a Valuable Endpoint for Early Development HBV Trials"], ["Oliver Lenz", 2017, "Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Clearance and could be a Valuable Endpoint for Early Development HBV Trials"], ["Filip De Ridder", 2017, "Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Clearance and could be a Valuable Endpoint for Early Development HBV Trials"], ["Willem Talloen", 2017, "Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Clearance and could be a Valuable Endpoint for Early Development HBV Trials"], ["George Wu", 2017, "Variability in Hepatitis B surface Antigen (HBsAg) Levels during Nucleos (t) ide (NUC) Therapy in Subgroups of Immune Active CHB Patients"], ["Qin Zhang", 2017, "Serum HBV RNA level predicts response to peginterferon add-on therapy for HBeAg-positive chronic hepatitis B"], ["van Campenhout", 2017, "Serum HBV RNA level predicts response to peginterferon add-on therapy for HBeAg-positive chronic hepatitis B"], ["Adrian Streinu-Cercel", 2017, "Serum HBV RNA level predicts response to peginterferon add-on therapy for HBeAg-positive chronic hepatitis B"], ["Margo J. y", 2017, "Serum HBV RNA level predicts response to peginterferon add-on therapy for HBeAg-positive chronic hepatitis B"], ["Jiyao Wang", 2017, "Serum HBV RNA level predicts response to peginterferon add-on therapy for HBeAg-positive chronic hepatitis B"], ["Abbas Dehghan", 2017, "Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian randomization study"], ["Symen Ligthart", 2017, "Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian randomization study"], ["Jana Nano", 2017, "Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian randomization study"], ["Taulant Muka", 2017, "Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian randomization study"], ["Jiawei Cao", 2017, "Durability of response after hepatitis B surface antigen seroclearance during nucleos (t) ide analogue treatment in a multiethnic cohort of chronic hepatitis B patients \u2026"], ["Stijn Van Hees", 2017, "Durability of response after hepatitis B surface antigen seroclearance during nucleos (t) ide analogue treatment in a multiethnic cohort of chronic hepatitis B patients \u2026"], ["Thomas Vanwolleghem", 2017, "Durability of response after hepatitis B surface antigen seroclearance during nucleos (t) ide analogue treatment in a multiethnic cohort of chronic hepatitis B patients \u2026"], ["GM Subramanian", 2017, "Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and \u2026"], ["K Agarwal", 2017, "Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and \u2026"], ["L Lin", 2017, "Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and \u2026"], ["WL Chuang", 2017, "Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and \u2026"], ["Juliana Fittipaldi", 2017, "Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study"], ["Pavel Taimr", 2017, "Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study"], ["Saeed Almarzooqi", 2017, "Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia"], ["Joel S Emery", 2017, "Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia"], ["Magdalena Kuczynski", 2017, "Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia"], ["Bart L Haagmans", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["Anita C Sch\u00fcrch", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["Charles A Boucher", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["Albert DME Osterhaus", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["Saskia L Smits", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["Isabel Najera", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["Gadissa Bedada Hundie", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["Sophie Le Pogam", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["V Stalin Raj", 2017, "Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment na\u00efve patients"], ["SM Harrell", 2017, "The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir\u2010based regimens"], ["SH Al Marzooqi", 2017, "The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir\u2010based regimens"], ["J Karkada", 2017, "The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir\u2010based regimens"], ["Andres Duarte\u2010Rojo", 2017, "The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir\u2010based regimens"], ["JS Klair", 2017, "The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir\u2010based regimens"], ["KD Rhodes", 2017, "The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir\u2010based regimens"], ["Jorg Petersen", 2017, "Hepatitis B virus infection."], ["Henry L Chan", 2017, "Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A \u2026"], ["Wan-Long Chuang", 2017, "Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A \u2026"], ["Alain Chan", 2017, "Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A \u2026"], ["Audrey Lau", 2017, "Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A \u2026"], ["Magdy Elkhashab", 2017, "Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS)"], ["Mustafa Celen", 2017, "Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic \u2026"], ["Akash Shukla", 2017, "Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic \u2026"], ["Marina Osipenko", 2017, "Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic \u2026"], ["Qing Guo", 2017, "Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos (t) ide analogue: a randomized \u2026"], ["Simin Guo", 2017, "Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos (t) ide analogue: a randomized \u2026"], ["Pauline Arends", 2017, "Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos (t) ide analogue: a randomized \u2026"], ["Ji-Yao Wang", 2017, "Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos (t) ide analogue: a randomized \u2026"], ["Ning Ping Zhang", 2017, "Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos (t) ide analogue: a randomized \u2026"], ["Anna Suk\u2010Fong Lok", 2017, "Determination of hepatitis B phenotype using biochemical and serological markers"], ["Lewis Roberts", 2017, "Determination of hepatitis B phenotype using biochemical and serological markers"], ["Jeffrey Teckman", 2017, "Determination of hepatitis B phenotype using biochemical and serological markers"], ["MR Hodges", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["N Selzner", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["J Echeverri", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["R Persson", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["VN Spetzler", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["JM Kaths", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["N Goldaracena", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["DR Grant", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["M Selzner", 2017, "Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation\u2014A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion"], ["Seng Gee Lim", 2017, "Ethics and hepatitis B cure research"], ["Sharon R Lewin", 2017, "Ethics and hepatitis B cure research"], ["Jeremy Sugarman", 2017, "Ethics and hepatitis B cure research"], ["Yazdan Yazdanpanah", 2017, "Ethics and hepatitis B cure research"], ["Harald Hofer", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Bart J Veldt", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Stanislas Pol", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Conrado M Fern\u00e1ndez-Rodr\u00edguez", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Savino Bruno", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Piero L Almasio", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Vito Di Marco", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Ricardo Moreno-Otero", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Ola Weiland", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Rolf Hultcrantz", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Maria Trapero-Marugan", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Nathalie Ganne-Carri\u00e9", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Karoline Rutter", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Vincenza Calvaruso", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Roberta D\u2019Ambrosio", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Soo Aleman", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Vincent Mallet", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Sonia Alonso", 2017, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication"], ["Chunxiu Zhong", 2017, "Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of Nucleos (t) ide analogue therapy in patients with chronic hepatitis B: a \u2026"], ["Jose D Debes", 2017, "Hepatitis C treatment and liver cancer recurrence: cause for concern?"], ["Markus Cornberg", 2017, "The role of quantitative hepatitis B surface antigen revisited"], ["Vincent Wai-Sun Wong", 2017, "The role of quantitative hepatitis B surface antigen revisited"], ["Young Suk Lim", 2017, "PS 2-2: Improved Bone and Renal Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in CHB Patients"], ["Andrea Cathcart", 2017, "O-063: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients with HBeAg-positive CHB patients"], ["Kyungpil Kim", 2017, "O-066: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in HBeAg-Negative CHB Patients at Week 96"], ["Mustafa K Celen", 2017, "O-066: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in HBeAg-Negative CHB Patients at Week 96"], ["Henry Chan", 2017, "O-066: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in HBeAg-Negative CHB Patients at Week 96"], ["Calvin Pan", 2017, "O-066: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in HBeAg-Negative CHB Patients at Week 96"], ["Seung Kew Yoon", 2017, "O-066: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in HBeAg-Negative CHB Patients at Week 96"], ["Sven Francque", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Harry L Janssens", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Dirk Sprengers", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Hans Van Vlierberghe", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Christophe Moreno", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Thomas Serste", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Stefan Bourgeois", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Isabell Colle", 2017, "Cessation of nucleos (t) ide analogue treatment after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study"], ["Vasiliki Ligoura", 2017, "Moving from early to moderate or advanced biochemical disease stage during follow-up is associated with an increasing risk of clinical events in primary biliary cholangitis \u2026"], ["Ann-Arosa Floreani", 2017, "Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after \u2026"], ["Frank Tacke", 2017, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection"], ["George Papatheodoridis", 2017, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection"], ["Lucio Gama", 2017, "Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection"], ["Sarah L Price", 2017, "Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection"], ["Jun Hou", 2017, "Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection"], ["Pim J French", 2017, "Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection"], ["Kim Kreefft", 2017, "Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection"], ["YS Lim", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["N Izumi", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["N Bhardwaj", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["K Kim", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["SH Ahn", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["M Osipenko", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["H Chan", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["C Pan", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["MK Celen", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["H Trinh", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["AH Lau", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["A Shukla", 2017, "A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96"], ["G Heymann", 2017, "Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions?"], ["A Aquino", 2017, "Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions?"], ["M Van Tilborg", 2017, "Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions?"], ["JJ Fischer", 2017, "Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection"], ["M Grossmann", 2017, "Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection"], ["AJ van Vuuren", 2017, "Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection"], ["D Deichsel", 2017, "Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection"], ["A Boonstra", 2017, "Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection"], ["MJ van Campenhout", 2017, "Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection"], ["Y Mori", 2017, "A randomized controlled trial of US vs US+ biomarkers for the diagnosis of hepatocellular carcinoma: an interim report"], ["H Yamada", 2017, "A randomized controlled trial of US vs US+ biomarkers for the diagnosis of hepatocellular carcinoma: an interim report"], ["R Chapman", 2017, "Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial"], ["J McHutchison", 2017, "Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial"], ["M Manns", 2017, "Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial"], ["B McColgan", 2017, "Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial"], ["C Jia", 2017, "Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial"], ["N Afdhal", 2017, "Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial"], ["D Goldstein", 2017, "Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis \u2026"], ["S Kleinstein", 2017, "Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis \u2026"], ["P Shea", 2017, "Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis \u2026"], ["NF LaRusso", 2017, "Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years"], ["GN Dalekos", 2017, "Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years"], ["PJ Trivedi", 2017, "Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years"], ["HJ Metselaar", 2017, "Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study"], ["LJM Alferink", 2017, "Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study"], ["JD Schoufour", 2017, "Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study"], ["P Taimr", 2017, "Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study"], ["AM Ikram", 2017, "Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study"], ["N Furusyo", 2017, "A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety \u2026"], ["A Cathcart", 2017, "A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety \u2026"], ["KT Yoon", 2017, "A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety \u2026"], ["A Lau", 2017, "A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety \u2026"], ["M Sharma", 2017, "A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety \u2026"], ["B Pinarbasi", 2017, "Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B"], ["M Akdogan", 2017, "Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B"], ["K Simon", 2017, "Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B"], ["M Raptopoulou-Gigi", 2017, "Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B"], ["GW van Oord", 2017, "Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B"], ["RJ De Knegt", 2017, "Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals?"], ["J-M Pawlotsky", 2017, "Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals?"], ["I Younossi", 2017, "Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)"], ["N Tsai", 2017, "Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)"], ["M Stepanova", 2017, "Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)"], ["S Hunt", 2017, "Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)"], ["ZM Younossi", 2017, "Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)"], ["W Zanjir", 2017, "Impact of genotype 3 on clinical outcome in patients with hepatitis C: both diabetes meliitus and liver disease progression"], ["AJ Van Vuuren", 2017, "Serum hepatitis B virus RNA level is associated with hepatitis B virus genotype and BCP mutations in untreated patients with HBeAg positive chronic hepatitis B"], ["J Fischer", 2017, "Serum hepatitis B virus RNA level is associated with hepatitis B virus genotype and BCP mutations in untreated patients with HBeAg positive chronic hepatitis B"], ["F Van B\u00f6mmel", 2017, "Serum hepatitis B virus RNA level is associated with hepatitis B virus genotype and BCP mutations in untreated patients with HBeAg positive chronic hepatitis B"], ["NK Gatselis", 2017, "The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time"], ["JC Goet", 2017, "The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time"], ["HR Van Buuren", 2017, "The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time"], ["V Sozzi", 2017, "On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB"], ["D Colledge", 2017, "On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB"], ["JC Kiefte-deJong", 2017, "Animal protein is the most important macronutrient associated with non-alcoholic fatty liver disease in overweight participants: The Rotterdam Study"], ["OH Franco", 2017, "Animal protein is the most important macronutrient associated with non-alcoholic fatty liver disease in overweight participants: The Rotterdam Study"], ["B Veldt", 2017, "Animal protein is the most important macronutrient associated with non-alcoholic fatty liver disease in overweight participants: The Rotterdam Study"], ["Vinzent Spetzler", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["Nazia Selzner", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["Moritz Kaths", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["Nicolas Goldaracena", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["Vera Cherepanov", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["Markus Selzner", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["Juan Echeverri", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["David Grant", 2017, "Liver Graft Modification Using Warm Ex Vivo Perfusion-It Isn't Only About Rescuing Marginal Grafts"], ["John McHutchison", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Sibrat Acharya", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Rajiv Mehta", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Yiwei Lu", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Phillip Dinh", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Tak Yin Owen Tsang", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Aric Josun Hui", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Abhijit Chowdhury", 2017, "A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy \u2026"], ["Wing Yin Tang", 2017, "Multiple biopsy passes and the risk of complications of percutaneous liver biopsy"], ["Dave Sprengers", 2017, "Multiple biopsy passes and the risk of complications of percutaneous liver biopsy"], ["Jeoffrey NL Schouten", 2017, "Multiple biopsy passes and the risk of complications of percutaneous liver biopsy"], ["T Hansen", 2016, "Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues"], ["Michael P Manns", 2016, "Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis"], ["Florence Wong", 2016, "Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis"], ["Alnoor Ramji", 2016, "Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis"], ["Katja Deterding", 2016, "Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis"], ["Frank Lammert", 2016, "Real\u2010world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["Jean\u2010Fran\u00e7ois Dufour", 2016, "Real\u2010world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["Carin A Uyl\u2010de Groot", 2016, "Real\u2010world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["Remziye Zaim", 2016, "Real\u2010world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["Pierre Pradat", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Ivana Carey", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Teresa A Santantonio", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Ashley Brown", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Ye H Oo", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["VIRGIL Surveillance Study Group (European surveillance network for vigilance against viral resistance)", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Jurri\u00ebn GP Reijnders", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Massimo Fasano", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["J\u00f6rg Petersen", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["David Mutimer", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Tania M Welzel", 2016, "Flares during long\u2010term entecavir therapy in chronic hepatitis B"], ["Subrat K Acharya", 2016, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non \u2026"], ["GS-US-320-0110 Investigators", 2016, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non \u2026"], ["Aric-Josun Hui", 2016, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind \u2026"], ["Alessandra Mangia", 2016, "Safety and efficacy of GS-4774 in combination with TDF in patients with chronic hepatitis B not on antiviral medication"], ["Timothy C Rodell", 2016, "Safety and efficacy of GS-4774 in combination with TDF in patients with chronic hepatitis B not on antiviral medication"], ["Xiaoli Ma", 2016, "Safety and efficacy of GS-4774 in combination with TDF in patients with chronic hepatitis B not on antiviral medication"], ["Aldo J Montano-Loza", 2016, "Comparable beneficial effects of beza-and fenofibrate in primary biliary cholangitis. An international study in UDCA-treated individuals"], ["Ulrich Beuers", 2016, "Comparable beneficial effects of beza-and fenofibrate in primary biliary cholangitis. An international study in UDCA-treated individuals"], ["Farid Gaouar", 2016, "Comparable beneficial effects of beza-and fenofibrate in primary biliary cholangitis. An international study in UDCA-treated individuals"], ["Nora Cazzagon", 2016, "Comparable beneficial effects of beza-and fenofibrate in primary biliary cholangitis. An international study in UDCA-treated individuals"], ["Mark S Sulkowski", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["AKM Rahman", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Mario Ostrowski", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Sonya A MacParland", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Jordan J Feid", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Leen Vijgen", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Camelia Capraru", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Sharon Yoon", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Analiza Aquino", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Mohamed Gamil", 2016, "Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients"], ["Spyros I Siakavellas", 2016, "The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients"], ["Jose L Calleja", 2016, "The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients"], ["Jiannis Vlachogiannakos", 2016, "The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients"], ["Juan de la Revilla", 2016, "The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients"], ["Alex J Thompson", 2016, "HBsAg levels vary across the natural history of CHB and are influenced by HBV genotype and the emergence of basal core promoter variants."], ["Scott Bowden", 2016, "HBsAg levels vary across the natural history of CHB and are influenced by HBV genotype and the emergence of basal core promoter variants."], ["Tina Sozzi", 2016, "HBsAg levels vary across the natural history of CHB and are influenced by HBV genotype and the emergence of basal core promoter variants."], ["Oscar H Franco Duran", 2016, "Coffee & herbal tea consumption is protective of liver stiffness in the general population: The Rotterdam Study"], ["Jessica C Jong", 2016, "Coffee & herbal tea consumption is protective of liver stiffness in the general population: The Rotterdam Study"], ["Josje Schoufour", 2016, "Coffee & herbal tea consumption is protective of liver stiffness in the general population: The Rotterdam Study"], ["RB Takkenberg", 2016, "High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up"], ["Meike H van der Ree", 2016, "High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up"], ["Martine W Peters", 2016, "High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up"], ["Femke Stelma", 2016, "High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up"], ["Hans L Zaaijer", 2016, "High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up"], ["Annikki de Niet", 2016, "High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up"], ["Louis Jansen", 2016, "High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up"], ["Naoky Cs C Tsai", 2016, "Safety and efficacy of GS-9620 in virally-suppressed patients with chronic hepatitis B"], ["AJ Hui", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["G Subramanian", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["S Pianko", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["T Stepanova", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["B Massetto", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["R Mehta", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["S Acharya", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["W Cheng", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["P Dinh", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["W Seto", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy \u2026"], ["S Strasser", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["S Roberts", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["H Kim", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["A Hui", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["P Angus", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["W Chuang", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["C Chen", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["T Tsang", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["A Chowdhury", 2016, "A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety \u2026"], ["Aamir G Khan", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Catherine W Spearman", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Andre Elewaut", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Chau-Ting Yeh", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Zaigham Abbas", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Vasily Isakov", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Suzane K Ono", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Jose Sollano", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Anton LeMair", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Man Fung Yuen", 2016, "World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015"], ["Beatrice Cherubini", 2016, "Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up"], ["Alex JV Thompson", 2016, "Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up"], ["Michelle Martinot-Peignoux", 2016, "Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up"], ["Mircea Mihai Diculescu", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Isabelle Klauck", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Wojciech Wasiak", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Tomasz Mach", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Renate Heyne", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Adrian Eugen Goldis", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Jolanta Bia\u0142kowska-Warzecha", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Soumaya Bendahmane", 2016, "Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure"], ["Robin P Peeters", 2016, "Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam Study"], ["Layal Chaker", 2016, "Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam Study"], ["Arjola Bano", 2016, "Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam Study"], ["Gertine W van Oord", 2016, "Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF)"], ["Jurrien GP Reijnders", 2016, "Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF)"], ["Eric TTL Tjwa", 2016, "Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF)"], ["Roeland Zoutendijk", 2016, "Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF)"], ["Andrea M Woltman", 2016, "Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF)"], ["Lauke L Boeijen", 2016, "Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF)"], ["MJ Sinnige", 2016, "HLA\u2010C and KIR combined genotype as new response marker for HBeAg\u2010positive chronic hepatitis B patients treated with interferon\u2010based combination therapy"], ["Leo Jansen", 2016, "HLA\u2010C and KIR combined genotype as new response marker for HBeAg\u2010positive chronic hepatitis B patients treated with interferon\u2010based combination therapy"], ["Karel A van Dort", 2016, "HLA\u2010C and KIR combined genotype as new response marker for HBeAg\u2010positive chronic hepatitis B patients treated with interferon\u2010based combination therapy"], ["Charles Kooperberg", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Jeffrey Haessler", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Manish Gala", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Bernhard Boehm", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Dan M Roden", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Paul M Ridker", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Charlotte Andersson", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Anne Tybj\u00e6rg-Hansen", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Andrew T Chan", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Raymond Noordam", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Stefan Stender", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Andr\u00e9 G Uitterlinden", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Lu-Chen Weng", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Janey L Wiggs", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Immaculata De Vivo", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Rulla M Tamimi", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Amit D Joshi", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Stephan Buch", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Jae H Kang", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Wolfgang Lieb", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Christian M Shaffer", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Weihong Tang", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Alex P Reiner", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Peter Kraft", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Paul L Auer", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Yoshiyuki Wakabayashi", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Andrew D Johnson", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["John D Eicher", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Peter E Weeke", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Wolfgang Kratzer", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Uwe V\u00f6lker", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Bruno H Stricker", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Henry V\u00f6lzke", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Louis R Pasquale", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Jun Zhu", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Constance Chen", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Alexander Teumer", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Hyon Choi", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["B\u00f8rge G Nordestgaard", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["David Ellinghaus", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Pamela L Lutsey", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Clemens Schafmayer", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["David J Hunter", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Aaron R Folsom", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Charles Fuchs", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Eric Rimm", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Jochen Hampe", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Gary Curhan", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Joshua C Denny", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Daniel I Chasman", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Frank Hu", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Lynda M Rose", 2016, "Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies"], ["Gurtej Malhi", 2016, "The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection"], ["Mahmoud Abu-Amara", 2016, "The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection"], ["Suraj Sharma", 2016, "The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection"], ["Aniek van den Bosch", 2016, "Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism"], ["Sonja I Buschow", 2016, "Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism"], ["Nadine van Montfoort", 2016, "Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism"], ["Hassan Javanbakht", 2016, "Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism"], ["Hilde Brouwers", 2016, "Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism"], ["Evelyn van der Aa", 2016, "Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism"], ["Misael Uribe", 2016, "Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis"], ["Alejandra Altamirano-Barrera", 2016, "Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis"], ["Nahum M\u00e9ndez-S\u00e1nchez", 2016, "Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis"], ["R Schindler", 2016, "long\u2010term safety of nucleoside and nucleotide analogues in HBV\u2010monoinfected patients"], ["HLY Chan", 2016, "long\u2010term safety of nucleoside and nucleotide analogues in HBV\u2010monoinfected patients"], ["SI Strasser", 2016, "long\u2010term safety of nucleoside and nucleotide analogues in HBV\u2010monoinfected patients"], ["Q Zhang", 2016, "Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen\u2013positive chronic hepatitis B patients"], ["Nong Zhang", 2016, "Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen\u2013positive chronic hepatitis B patients"], ["Jinxia Wang", 2016, "Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen\u2013positive chronic hepatitis B patients"], ["SD Pas", 2016, "Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen\u2013positive chronic hepatitis B patients"], ["MJ Sonneveld", 2016, "Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen\u2013positive chronic hepatitis B patients"], ["MJH van Campenhout", 2016, "Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen\u2013positive chronic hepatitis B patients"], ["Ulus S Akarca", 2016, "Peginterferon add\u2010on results in more HBsAg decline compared to monotherapy in HBeAg\u2010positive chronic hepatitis B patients"], ["Ningping Zhang", 2016, "Peginterferon add\u2010on results in more HBsAg decline compared to monotherapy in HBeAg\u2010positive chronic hepatitis B patients"], ["W Peter Hofmann", 2016, "Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis"], ["Lawrence Serfaty", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Megan Wind-Rotolo", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Pei-Jer Chen", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Dong Xu", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["LIRA-B Study Team", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Carla S Coffin", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["David Cohen", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Ting-Tsung Chang", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Elizabeth Cooney", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Linda Critelli", 2016, "Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"], ["Giampaolo Mangia", 2016, "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy"], ["Raul E Aguilar Schall", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["Eduardo B Martins", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["Stuart C Gordon", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["Tarik Asselah", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["W Ray Kim", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["Leland J Yee", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["Rohit Loomba", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["Jeffrey D Bornstein", 2016, "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients"], ["Maureen Sie", 2016, "Making Sense: Narrativity, Interpretation and Responsibility Introduction"], ["Leon de Bruin", 2016, "Making Sense: Narrativity, Interpretation and Responsibility Introduction"], ["Steven-Huy B Han", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["Natalie Bzowej", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["James W Keith", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["Robert L Carithers", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["Coleman Smith", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["Keith W Torrey", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["Danielle L Levine", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["Steven Belle", 2016, "Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B"], ["Jildou Hoekstra", 2016, "GI ischemia in patients with portal vein thrombosis: a prospective cohort study"], ["D\u00e9sir\u00e9e van Noord", 2016, "GI ischemia in patients with portal vein thrombosis: a prospective cohort study"], ["Jihan Harki", 2016, "GI ischemia in patients with portal vein thrombosis: a prospective cohort study"], ["Ernst J Kuipers", 2016, "GI ischemia in patients with portal vein thrombosis: a prospective cohort study"], ["Ella AM Van Der Voort", 2016, "Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam Study"], ["Tamar Nijsten", 2016, "Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam Study"], ["Marlies Wakkee", 2016, "Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam Study"], ["Edith M Koehler", 2016, "Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam Study"], ["Ambreen Arif", 2016, "New therapeutic agents for chronic hepatitis B"], ["Andrew K Burroughs", 2016, "Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study"], ["Lloren\u00e7 Caballeria", 2016, "Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study"], ["Michelle Spaan", 2016, "Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment"], ["Anne Halenius", 2016, "The murine cytomegalovirus immunoevasin gp40 binds MHC class I molecules to retain them in the early secretory pathway"], ["Susanne Fritzsche", 2016, "The murine cytomegalovirus immunoevasin gp40 binds MHC class I molecules to retain them in the early secretory pathway"], ["Irina Majoul", 2016, "The murine cytomegalovirus immunoevasin gp40 binds MHC class I molecules to retain them in the early secretory pathway"], ["Mohamed Aboelmagd", 2016, "The murine cytomegalovirus immunoevasin gp40 binds MHC class I molecules to retain them in the early secretory pathway"], ["Maro Iliopoulou", 2016, "The murine cytomegalovirus immunoevasin gp40 binds MHC class I molecules to retain them in the early secretory pathway"], ["Hl Chan", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["M Martinot Peignoux", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["Be Hansen", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["Yf Liaw", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["Wp Brouwer", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["Hl Janssen", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["MAURIZIA ROSSANA Brunetto", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["B Cherubini", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["P Arends", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["Aj Thompson", 2016, "Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up"], ["Vw Wong", 2016, "The role of quantitative hepatitis B surface antigen revisited"], ["Moniek PM de Maat", 2016, "Is von Willebrand factor level a predictive marker of liver fibrosis in the general population? The Rotterdam Study"], ["Frank WG Leebeek", 2016, "Is von Willebrand factor level a predictive marker of liver fibrosis in the general population? The Rotterdam Study"], ["Daan W Loth", 2016, "Is von Willebrand factor level a predictive marker of liver fibrosis in the general population? The Rotterdam Study"], ["Aur\u00e9lie Plessier", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["Pierre-Emmanuel Rautou", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["Jonel Trebicka", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["Dominique C Valla", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["Fanny Turon", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["Luc Lasser", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["Juan Carlos Garcia-Pag\u00e1n", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["Massimo Primignani", 2016, "Genetic variants associated with deep vein thrombosis are not a risk factor for splanchnic vein thrombosis"], ["European Association for the Study of the Liver", 2016, "EASL Clinical Practice Guidelines: Vascular diseases of the liver."], ["Vincenzo Ronca", 2016, "Primary Biliary Cholangitis at a Young Age: Clinical Characteristics and Prognosis"], ["Silvia Diotti", 2016, "Primary Biliary Cholangitis at a Young Age: Clinical Characteristics and Prognosis"], ["Loren\u00e7 Caballeria", 2016, "Biochemical patterns of alkaline phosphatase and bilirubin levels in relation to clinical outcomes in UDCA-treated PBC patients-an international study"], ["Teru Kumagli", 2016, "Biochemical patterns of alkaline phosphatase and bilirubin levels in relation to clinical outcomes in UDCA-treated PBC patients-an international study"], ["Bettina E Hanssen", 2016, "Biochemical patterns of alkaline phosphatase and bilirubin levels in relation to clinical outcomes in UDCA-treated PBC patients-an international study"], ["F van Bommel", 2016, "Nucleios (t) ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B"], ["TERESA ANTONIA Santantonio", 2016, "Nucleios (t) ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B"], ["I Carey", 2016, "Nucleios (t) ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B"], ["P Pradat", 2016, "Nucleios (t) ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B"], ["AM Woltman", 2016, "Similar Frequencies, Phenotype and Activation Status of Intrahepatic NK Cells in Chronic HBV Patients after Long-Term Treatment with Tenofovir Disoproxil Fumarate (TDF)"], ["ET Tjwa", 2016, "Similar Frequencies, Phenotype and Activation Status of Intrahepatic NK Cells in Chronic HBV Patients after Long-Term Treatment with Tenofovir Disoproxil Fumarate (TDF)"], ["R Zoutendijk", 2016, "Similar Frequencies, Phenotype and Activation Status of Intrahepatic NK Cells in Chronic HBV Patients after Long-Term Treatment with Tenofovir Disoproxil Fumarate (TDF)"], ["LL Boeijen", 2016, "Similar Frequencies, Phenotype and Activation Status of Intrahepatic NK Cells in Chronic HBV Patients after Long-Term Treatment with Tenofovir Disoproxil Fumarate (TDF)"], ["Y-S Lim", 2016, "A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: week 48 efficacy and safety results"], ["JG McHutchison", 2016, "A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: week 48 efficacy and safety results"], ["SK Acharya", 2016, "A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: week 48 efficacy and safety results"], ["W-L Chuang", 2016, "A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: week 48 efficacy and safety results"], ["TYO Tsang", 2016, "A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-positive chronic HBV: week 48 efficacy and safety results"], ["C-Y Chen", 2016, "A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-positive chronic HBV: week 48 efficacy and safety results"], ["B Stricker", 2016, "Cholestasis is not Associated with Liver Stiffness in a Population-Based Cohort"], ["J Schouten", 2016, "Cholestasis is not Associated with Liver Stiffness in a Population-Based Cohort"], ["E Plompen", 2016, "Cholestasis is not Associated with Liver Stiffness in a Population-Based Cohort"], ["A Hofman", 2016, "Cholestasis is not Associated with Liver Stiffness in a Population-Based Cohort"], ["T Yu", 2016, "Using Off-Treatment HBV DNA Levels to Predict Alt Relapse after Nucleos (t) ide Analogue Discontinuation: A Prospective Cohort Study"], ["Z Li", 2016, "Using Off-Treatment HBV DNA Levels to Predict Alt Relapse after Nucleos (t) ide Analogue Discontinuation: A Prospective Cohort Study"], ["J Cao", 2016, "Using Off-Treatment HBV DNA Levels to Predict Alt Relapse after Nucleos (t) ide Analogue Discontinuation: A Prospective Cohort Study"], ["S Cai", 2016, "Using Off-Treatment HBV DNA Levels to Predict Alt Relapse after Nucleos (t) ide Analogue Discontinuation: A Prospective Cohort Study"], ["J Peng", 2016, "Using Off-Treatment HBV DNA Levels to Predict Alt Relapse after Nucleos (t) ide Analogue Discontinuation: A Prospective Cohort Study"], ["CL Bowlus", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["RP Myers", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["AJ Montano-Loza", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["AJ Muir", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["DB Goldstein", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["SE Kleinstein", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["ML Shiftman", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["PR Shea", 2016, "Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum \u2026"], ["J Cheng", 2016, "Previous Interferon Treatment Failure is Associated with Avery Low Chance of Response to Peginterferon Retreatment in HBeAg-Positive Chronic Hepatitis B: Pooled Analysis of Two \u2026"], ["J Hou", 2016, "Previous Interferon Treatment Failure is Associated with Avery Low Chance of Response to Peginterferon Retreatment in HBeAg-Positive Chronic Hepatitis B: Pooled Analysis of Two \u2026"], ["F Wong", 2016, "Safety of direct-acting antivirals-based therapy for the treatment of patients with chronic hepatitis C virus infection and cirrhosis: results from an international multicenter \u2026"], ["K Deterding", 2016, "Safety of direct-acting antivirals-based therapy for the treatment of patients with chronic hepatitis C virus infection and cirrhosis: results from an international multicenter \u2026"], ["A Ramji", 2016, "Safety of direct-acting antivirals-based therapy for the treatment of patients with chronic hepatitis C virus infection and cirrhosis: results from an international multicenter \u2026"], ["AJ van der Meer", 2016, "Safety of direct-acting antivirals-based therapy for the treatment of patients with chronic hepatitis C virus infection and cirrhosis: results from an international multicenter \u2026"], ["FJ ten Kate", 2016, "Polymorphisms of HLA-DPB1 are Associated with Long-Term Clinical Outcome in a Diverse Cohort of Chronic Hepatitis B Patients"], ["Victor CK Lo", 2016, "IFN-Based Therapy and Management of Patients"], ["Paula J Biesta", 2016, "The effect of chronic hepatitis B virus infection on BDCA3+ dendritic cell frequency and function"], ["L Lapointe\u2010Shaw", 2016, "Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes"], ["AC Cheung", 2016, "Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes"], ["J Meza\u2010Cardona", 2016, "Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes"], ["J De Bruijne", 2016, "Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA\u2010122 levels without affecting other micro RNA s in plasma"], ["AJ Van Der Meer", 2016, "Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA\u2010122 levels without affecting other micro RNA s in plasma"], ["AC Van Nuenen", 2016, "Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA\u2010122 levels without affecting other micro RNA s in plasma"], ["MH Van der Ree", 2016, "Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA\u2010122 levels without affecting other micro RNA s in plasma"], ["S Ottosen", 2016, "Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA\u2010122 levels without affecting other micro RNA s in plasma"], ["Laurent Castera", 2016, "Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study"], ["Jan NM IJzermans", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Alexander Pedroza-Gonzalez", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Dirk Grunhagen", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["TC Khe Tran", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Katharina Biermann", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Simar Pal Singh", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Jaap Kwekkeboom", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Patrick PC Boor", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Guoying Zhou", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Cornelis Verhoef", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Qiuwei Pan", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Jeroen de Jonge", 2015, "GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo"], ["Caitlin Yuan", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Jeffery Teckman", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Rosemary Swan", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Shirley Montanye", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Hongxia Li", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Laurie A Rodgers-Augustyniak", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Karen Murray", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Geoffrey Johnson", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Kim Kafka", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Adrian Di Bisceglie", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Barbara Walters", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Shannon Fleck", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Kara L Cooper", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Shannon M Riggs", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Norberto Rodriguez-Baez", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Camille Langlois", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Constance O'Connor", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Karen F Murray", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Sarah Jane Schwarzenberg", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Ruosha Li", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Lilia Milkova Ganova-Raeva", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Yona Keich Cloonan", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Douglas Mogul", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Robert Anders", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Simon Ling", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Rosemary Nagy", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Kathleen Schwarz", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Joan M MacGregor", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Michelle Danielson", 2015, "Children with chronic hepatitis B in the United States and Canada"], ["Nanda C Krak", 2015, "Liver contrast-enhanced ultrasound improves detection of liver metastases in patients with pancreatic or periampullary cancer"], ["Casper HJ van Eijck", 2015, "Liver contrast-enhanced ultrasound improves detection of liver metastases in patients with pancreatic or periampullary cancer"], ["Chulja J Pek", 2015, "Liver contrast-enhanced ultrasound improves detection of liver metastases in patients with pancreatic or periampullary cancer"], ["Vivian L Jongerius", 2015, "Liver contrast-enhanced ultrasound improves detection of liver metastases in patients with pancreatic or periampullary cancer"], ["Watcharasak Chotiyaputta", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Jerzy Jaroszewicz", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Necati \u00d6rmeci", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Resat Ozaras", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Giuseppe Montalto", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Tawesak Tanwandee", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Henk Reesink", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Xieer Liang", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Chen Liang", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Karin Kozbial", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Monika Pazgan-Simon", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Shalom Chen", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Fulya Gunsar", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Nattiya Hirankarn", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Rozita Razavi", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Erkin Oztas", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Vincent Wong", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Zwier Groothuismink", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Willem Brouwer", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Filiz Akyuz", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Pisit Tangkijvanich", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Wen Hong Zhang", 2015, "Genetic Variation rs16937012 near the NCOA2 Gene Predicts Sustained Response to Interferon in Chronic Hepatitis B patients: the GIANT-B study: LB-8"], ["Annemiek A van der Eijk", 2015, "Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States"], ["Julie K Heimbach", 2015, "Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States"], ["Kymberly D Watt", 2015, "Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States"], ["Ludi Koning", 2015, "Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States"], ["Michael R Charlton", 2015, "Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States"], ["Teru Kumagi", 2015, "Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy"], ["HBRN", 2015, "Diabetes and prediabetes in patients with hepatitis B residing in North America"], ["Mauricio Lisker\u2010Melman", 2015, "Diabetes and prediabetes in patients with hepatitis B residing in North America"], ["Elizabeth M Brunt", 2015, "Diabetes and prediabetes in patients with hepatitis B residing in North America"], ["Arun Sanyal", 2015, "Diabetes and prediabetes in patients with hepatitis B residing in North America"], ["S Zeuzem", 2015, "Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["C Uyl-de Groot", 2015, "Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["F Lammert", 2015, "Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["J Dufour", 2015, "Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["A van der Meer", 2015, "Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["R Zaim", 2015, "Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis"], ["Douglas T Dieterich", 2015, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 update"], ["Ira M Jacobson", 2015, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 update"], ["Daryl T-Y Lau", 2015, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 update"], ["Paul Martin", 2015, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 update"], ["Ning-Ping Zhang", 2015, "Final Results of Peginterferon Alfa-2b Add-on during Long-term Nucleos (t) ide Analogue Therapy in HBeAg-positive Patients-a Multicenter Randomized Controlled Trial (PEGON \u2026"], ["Robert de Knegt", 2015, "Final Results of Peginterferon Alfa-2b Add-on during Long-term Nucleos (t) ide Analogue Therapy in HBeAg-positive Patients-a Multicenter Randomized Controlled Trial (PEGON \u2026"], ["Michael Charlton", 2015, "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC): 616"], ["Andrew Muir", 2015, "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC): 616"], ["Robert Myers", 2015, "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC): 616"], ["Christopher Bowlus", 2015, "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC): 616"], ["Aldo Montano-Loza", 2015, "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC): 616"], ["Kris Kowdley", 2015, "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC): 616"], ["Mitchell Shiffman", 2015, "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC): 616"], ["Adrian Streinu-cercel", 2015, "Hepatitis B Core-Related Antigen Levels are Inversely Correlated With Fibrosis Stage in HBeAg-Positive Chronic Hepatitis B: 1586"], ["Margo van Campenhout", 2015, "Hepatitis B Core-Related Antigen Levels are Inversely Correlated With Fibrosis Stage in HBeAg-Positive Chronic Hepatitis B: 1586"], ["Adriaan van der Meer", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["Khalid Mumtaz", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["Beate Sander", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["William Wong", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["Matt Kowgier", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["Sean Cleary", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["Hooman Zangneh", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["Chaim Bell", 2015, "Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response: 350"], ["Seng Lim", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Eduardo Martins", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Graham Foster", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Leland Yee", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Joerg Petersen", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Aric Hui", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Sang Ahn", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Giovanni Gaeta", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Prista Charuworn", 2015, "Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for \u2026"], ["Eberhard Renner", 2015, "Reducing Wait Times for Radiofrequency Ablation in Patients with Hepatocellular Carcinoma: A Quality Improvement Initiative at the Toronto Centre for Liver Disease.: 542"], ["Selim Gurel", 2015, "Association between ALT flares and HBeAg loss and HBsAg decline in Patients with Chronic Hepatitis B during treatment with Tenofovir Disoproxil Fumarate or Adefovir Dipivoxil: 2059"], ["Zahary Krastev", 2015, "Association between ALT flares and HBeAg loss and HBsAg decline in Patients with Chronic Hepatitis B during treatment with Tenofovir Disoproxil Fumarate or Adefovir Dipivoxil: 2059"], ["Geoffrey Dusheiko", 2015, "Association between ALT flares and HBeAg loss and HBsAg decline in Patients with Chronic Hepatitis B during treatment with Tenofovir Disoproxil Fumarate or Adefovir Dipivoxil: 2059"], ["Jun Cheng", 2015, "Week 24 HBsAg levels predict response to peginterferon alfa-2b in HBeAg-positive genotype B or C chronic hepatitis B patients not meeting a week 12 stopping-rule: 2013"], ["Jin-Lin Hou", 2015, "Week 24 HBsAg levels predict response to peginterferon alfa-2b in HBeAg-positive genotype B or C chronic hepatitis B patients not meeting a week 12 stopping-rule: 2013"], ["Alex Thompson", 2015, "Deletion of APOBEC3B is Associated With Hepatitis B eAg Status in Patients with Chronic HBV Infection: 1651"], ["Luting Zhuo", 2015, "Deletion of APOBEC3B is Associated With Hepatitis B eAg Status in Patients with Chronic HBV Infection: 1651"], ["Ondrej Podlaha", 2015, "Deletion of APOBEC3B is Associated With Hepatitis B eAg Status in Patients with Chronic HBV Infection: 1651"], ["Dongliang Ge", 2015, "Deletion of APOBEC3B is Associated With Hepatitis B eAg Status in Patients with Chronic HBV Infection: 1651"], ["Xin Guo", 2015, "Deletion of APOBEC3B is Associated With Hepatitis B eAg Status in Patients with Chronic HBV Infection: 1651"], ["Zhaoshi Jiang", 2015, "Deletion of APOBEC3B is Associated With Hepatitis B eAg Status in Patients with Chronic HBV Infection: 1651"], ["David Goldstein", 2015, "Deletion of APOBEC3B is Associated With Hepatitis B eAg Status in Patients with Chronic HBV Infection: 1651"], ["Adrianus van Nuenen", 2015, "Miravirsen Dosing in Chronic Hepatitis C Patients Results in a Significant Decrease in Plasma MicroRNA-122 Level but Does Not Affect Plasma Levels of other MicroRNAs: 2255"], ["Meike van der Ree", 2015, "Miravirsen Dosing in Chronic Hepatitis C Patients Results in a Significant Decrease in Plasma MicroRNA-122 Level but Does Not Affect Plasma Levels of other MicroRNAs: 2255"], ["Hendrik Reesink", 2015, "Miravirsen Dosing in Chronic Hepatitis C Patients Results in a Significant Decrease in Plasma MicroRNA-122 Level but Does Not Affect Plasma Levels of other MicroRNAs: 2255"], ["Neeltje Kootstra", 2015, "Miravirsen Dosing in Chronic Hepatitis C Patients Results in a Significant Decrease in Plasma MicroRNA-122 Level but Does Not Affect Plasma Levels of other MicroRNAs: 2255"], ["Soren Ottosen", 2015, "Miravirsen Dosing in Chronic Hepatitis C Patients Results in a Significant Decrease in Plasma MicroRNA-122 Level but Does Not Affect Plasma Levels of other MicroRNAs: 2255"], ["Victor Lo", 2015, "Nucleos (t) ide Analogue Discontinuation in Patients with HBsAg Loss: Sustained Off-treatment Response Independent of Anti-HBs Status: 1998"], ["Jay Hoofnagle", 2015, "Objective Determination of Hepatitis B Phenotype using Biochemical and Serological Markers: Immune Tolerant, Immune Active, Inactive Carrier and Indeterminant Status: 121"], ["Pim French", 2015, "Unique Liver Transcriptomic Profiles in chronic HBV: Intrinsic Intrahepatic Functional Clusters discriminate Distinct Clinical Phases: 1637"], ["Yilmaz Cakaloglu", 2015, "Early prediction of response to peginterferon for HBeAg-positive chronic hepatitis B using HBsAg levels at week 4 and week 8 of therapy: 2001"], ["Aman Arya", 2015, "Clinical Outcomes of Patients with Private vs. Public Drug Coverage for Treatment of Chronic Hepatitis B: 1556"], ["Sarah Kleinstein", 2015, "Whole-Genome Sequencing of Patients Achieving Hepatitis B Virus Serum Antigen Loss Following TDF Treatment: 2037"], ["Fiebo ten Kate", 2015, "The PAGE-B Score Accurately Predicts Clinical Outcome and Outperforms Other Biomarkers over 15 Years of Follow-up in a Diverse Cohort of Chronic Hepatitis B Patients: 1590"], ["Elisabeth Plompen", 2015, "The PAGE-B Score Accurately Predicts Clinical Outcome and Outperforms Other Biomarkers over 15 Years of Follow-up in a Diverse Cohort of Chronic Hepatitis B Patients: 1590"], ["Suzan Pas", 2015, "The PAGE-B Score Accurately Predicts Clinical Outcome and Outperforms Other Biomarkers over 15 Years of Follow-up in a Diverse Cohort of Chronic Hepatitis B Patients: 1590"], ["Robert de Man", 2015, "The PAGE-B Score Accurately Predicts Clinical Outcome and Outperforms Other Biomarkers over 15 Years of Follow-up in a Diverse Cohort of Chronic Hepatitis B Patients: 1590"], ["Jean-Francois Dufour", 2015, "The number needed to treat with interferon-free therapy to prevent one cirrhosis-related complication for individual HCV-infected patients with advanced fibrosis: 1166"], ["Wolf Hofmann", 2015, "The number needed to treat with interferon-free therapy to prevent one cirrhosis-related complication for individual HCV-infected patients with advanced fibrosis: 1166"], ["Giovanna Fattovich", 2015, "The number needed to treat with interferon-free therapy to prevent one cirrhosis-related complication for individual HCV-infected patients with advanced fibrosis: 1166"], ["Bart Veldt", 2015, "The number needed to treat with interferon-free therapy to prevent one cirrhosis-related complication for individual HCV-infected patients with advanced fibrosis: 1166"], ["Donatella Ieluzzi", 2015, "The number needed to treat with interferon-free therapy to prevent one cirrhosis-related complication for individual HCV-infected patients with advanced fibrosis: 1166"], ["Jos\u00e9 Calleja", 2015, "Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB \u2026"], ["Federica Invernizzi", 2015, "Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB \u2026"], ["Floriana Facchetti", 2015, "Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB \u2026"], ["Joel Karkada", 2015, "Frequency of Renal Impairment in Patients With Hepatitis C Infection Treated With Sofosbuvir-based Antiviral Regimens: 1099"], ["Kimberly Rhodes", 2015, "Frequency of Renal Impairment in Patients With Hepatitis C Infection Treated With Sofosbuvir-based Antiviral Regimens: 1099"], ["Sherrie Harrell", 2015, "Frequency of Renal Impairment in Patients With Hepatitis C Infection Treated With Sofosbuvir-based Antiviral Regimens: 1099"], ["Jagpal Klair", 2015, "Frequency of Renal Impairment in Patients With Hepatitis C Infection Treated With Sofosbuvir-based Antiviral Regimens: 1099"], ["Vincent Rijckborst", 2015, "Hepatitis B Core-Related Antigen Level Decline in the First 12 Weeks of Peginterferon Treatment is Associated with Response in HBeAg-Negative Chronic Hepatitis B: 1585"], ["JNM Ijzermans", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Pratika Y Hernanda", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Wanlu Cao", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["W Wang", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Kan Chen", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Liudmila L Kodach", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["SJA Bots", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["MJ Bruno", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Kostandinos Sideras", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["MP Peppelenbosch", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Andrew P Stubbs", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Juan Li", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["TLM Ten Hagen", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Asha M Das", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["RA De Man", 2015, "SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma"], ["Mark AA Claassen", 2015, "The intrahepatic T cell compartment does not normalize years after therapy-induced hepatitis C virus eradication"], ["Manuel Carballo", 2015, "Immigration and viral hepatitis"], ["Ye Oo", 2015, "Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians"], ["Teresa Santantonio", 2015, "Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians"], ["Peter D Siersema", 2015, "Real life adherence of chronic hepatitis B patients to entecavir treatment"], ["Karel J van Erpecum", 2015, "Real life adherence of chronic hepatitis B patients to entecavir treatment"], ["Lotte G van Vlerken", 2015, "Real life adherence of chronic hepatitis B patients to entecavir treatment"], ["Faydra I Lieveld", 2015, "Real life adherence of chronic hepatitis B patients to entecavir treatment"], ["Joop E Arends", 2015, "Real life adherence of chronic hepatitis B patients to entecavir treatment"], ["Michael T Dill", 2015, "An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B"], ["Valeska Terpstra", 2015, "An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B"], ["Neeltje A Kootstra", 2015, "An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B"], ["Markus H Heim", 2015, "An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B"], ["Zuzanna Makowska", 2015, "An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B"], ["Arno C Andeweg", 2015, "Re\u2010evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells"], ["ADME Osterhaus", 2015, "Re\u2010evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells"], ["Shanta Mancham", 2015, "Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors"], ["Gina S Garcia-Romo", 2015, "Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors"], ["Wojciech G Polak", 2015, "Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors"], ["Ernesto Vargas-Mendez", 2015, "Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors"], ["Dirk Gr\u00fcnhagen", 2015, "Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors"], ["Lianne van de Laar", 2015, "BDCA3 expression is associated with high IFN\u2010\u03bb production by CD34+\u2010derived dendritic cells generated in the presence of GM\u2010CSF, IL\u20104, and/or TGF\u2010\u03b2"], ["Elina Zuniga", 2015, "Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct"], ["Florence Herschke", 2015, "Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct"], ["Bart Haagmans", 2015, "Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct"], ["Martijn DB van de Garde", 2015, "Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct"], ["Paula Biesta", 2015, "Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct"], ["Sandra De Jonghe", 2015, "Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct"], ["Dowty Movita", 2015, "Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct"], ["M Abu\u2010Amara", 2015, "Reduced risk of relapse after long\u2010term nucleos (t) ide analogue consolidation therapy for chronic hepatitis B"], ["DKH Wong", 2015, "Reduced risk of relapse after long\u2010term nucleos (t) ide analogue consolidation therapy for chronic hepatitis B"], ["AA Van der Eijk", 2015, "Reduced risk of relapse after long\u2010term nucleos (t) ide analogue consolidation therapy for chronic hepatitis B"], ["Wlodzimierz Mazur", 2015, "Adding pegylated interferon to entecavir for hepatitis B e antigen\u2013positive chronic hepatitis B: A multicenter randomized trial (ARES study)"], ["Mihai Voiculescu", 2015, "Adding pegylated interferon to entecavir for hepatitis B e antigen\u2013positive chronic hepatitis B: A multicenter randomized trial (ARES study)"], ["Luc JW van der Laan", 2015, "Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function"], ["Marjoleine L Op den Brouw", 2015, "Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function"], ["Arjan Boltjes", 2015, "Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function"], ["LJ van der Laan", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["N Kamar", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["H Blokzijl", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["L Xu", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["X Zhou", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["Q Pan", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["PE de Ruiter", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["Y Wang", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["J Neyts", 2015, "P0488: Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection"], ["L Jansen", 2015, "P0490: NK cell dynamics in chronic hepatitis B patients are associated with HBsAg clearance after combination treatment with peginterferon ALFA-2A and adefovir"], ["EM van Leeuwen", 2015, "P0490: NK cell dynamics in chronic hepatitis B patients are associated with HBsAg clearance after combination treatment with peginterferon ALFA-2A and adefovir"], ["A de Niet", 2015, "P0490: NK cell dynamics in chronic hepatitis B patients are associated with HBsAg clearance after combination treatment with peginterferon ALFA-2A and adefovir"], ["EP Plompen", 2015, "P1286: Low prevalence of positive viral serology for HBV and HCV among a general dutch elderly population: Results from the rotterdam study"], ["BH Stricker", 2015, "P1286: Low prevalence of positive viral serology for HBV and HCV among a general dutch elderly population: Results from the rotterdam study"], ["J Wang", 2015, "P0613: Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection"], ["A Streinu-Cercel", 2015, "P0613: Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection"], ["MJ Van Campenhout", 2015, "P0613: Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection"], ["G van Oord", 2015, "P0613: Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection"], ["J De La Revilla", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["J Goulis", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["M Colombo", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["JL Calleja", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["O Kesk\u0131n", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["K Galanis", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["S Manolakopoulos", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["S Savvidou", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["R Id\u0131lman", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["C Yurdaydin", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["V Sypsa", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["I Vlachogiannakos", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["R Esteban", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["G Mangia", 2015, "P0641: Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the \u2026"], ["R de Groen", 2015, "P0695: Triple therapy for chronic HCV patients induces early activation of intrahepatic NK cells"], ["M Spaan", 2015, "P0695: Triple therapy for chronic HCV patients induces early activation of intrahepatic NK cells"], ["Y-F Liaw", 2015, "P0610: Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up"], ["M Martinot-Peignoux", 2015, "P0610: Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up"], ["HL-Y Chan", 2015, "P0610: Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up"], ["MR Brunetto", 2015, "P0610: Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up"], ["AJ Thompson", 2015, "P0610: Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up"], ["T Piratvisuth", 2015, "P0662: 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials"], ["J-L Hou", 2015, "P0662: 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials"], ["VW-S Wong", 2015, "P0662: 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials"], ["J-D Jia", 2015, "P0662: 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials"], ["JC Kiefte-de Jong", 2015, "P0983: Association between macro-nutrient intake and presence of nonalcoholic fatty liver disease in the Rotterdam study: a population-based study"], ["BJ Veldt", 2015, "P0983: Association between macro-nutrient intake and presence of nonalcoholic fatty liver disease in the Rotterdam study: a population-based study"], ["JM Neuberger", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["D Jones", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["M Heneghan", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["G Mells", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["GJ Alexander", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["RN Sandford", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["A Bathgate", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["S Sharp", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["M Mayo", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["M Aldersley", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["N Warheam", 2015, "P1147: Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest \u2026"], ["K Kreefft", 2015, "P0690: IFN-free therapy for chronic HCV: Transcriptomics and NK cell analyses"], ["J Keith", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["S Ho", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["C Smith", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["DT Lau", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["J-J Park", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["RK Sterling", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["DL Levine", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["ME Valiga", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["M Khalili", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["D Traum", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["WM Lee", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["RL Carithers", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["K Ojiro", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["K-M Chang", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["AS Wahed", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["G Johnson", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["ASF Lok", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["LR Roberts", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["M Betts", 2015, "P0460: CD3hiCD4-V\u03b39/V\u03b42 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B"], ["L Caballeria", 2015, "P1177: Risk factors for hepatic decompensation in primary biliary cirrhosis-results of an international follow up study of 2326 patients"], ["I Franceschet", 2015, "P1177: Risk factors for hepatic decompensation in primary biliary cirrhosis-results of an international follow up study of 2326 patients"], ["A Lleo", 2015, "P1177: Risk factors for hepatic decompensation in primary biliary cirrhosis-results of an international follow up study of 2326 patients"], ["N Zhang", 2015, "P0669: Consolidation therapy with entecavir can prevent post-treatment HBsAg rebound in HBeAg-positive chronic hepatitis B patients treated with peginterferon alpha"], ["US Akarca", 2015, "P0669: Consolidation therapy with entecavir can prevent post-treatment HBsAg rebound in HBeAg-positive chronic hepatitis B patients treated with peginterferon alpha"], ["NF Larusso", 2015, "P1180: Identification of pbc patients in need of additional therapy during the course of UDCA treatment-an international multicenter study"], ["MH Imam", 2015, "P1180: Identification of pbc patients in need of additional therapy during the course of UDCA treatment-an international multicenter study"], ["G Pieri", 2015, "P1180: Identification of pbc patients in need of additional therapy during the course of UDCA treatment-an international multicenter study"], ["K Boonstra", 2015, "P1180: Identification of pbc patients in need of additional therapy during the course of UDCA treatment-an international multicenter study"], ["T Kumagi", 2015, "P1180: Identification of pbc patients in need of additional therapy during the course of UDCA treatment-an international multicenter study"], ["A Par\u00e9s", 2015, "P1180: Identification of pbc patients in need of additional therapy during the course of UDCA treatment-an international multicenter study"], ["AC Andeweg", 2015, "P0456: Re-evaluation of HBV clinical phases by system biology identifies unappreciated roles for the innate immune response and B cells"], ["SD Diepstraten-Pas", 2015, "P0456: Re-evaluation of HBV clinical phases by system biology identifies unappreciated roles for the innate immune response and B cells"], ["AD Osterhaus", 2015, "P0456: Re-evaluation of HBV clinical phases by system biology identifies unappreciated roles for the innate immune response and B cells"], ["Aaron Isaacs", 2015, "Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study"], ["Cornelia M van Duijn", 2015, "Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study"], ["Bruno HC Stricker", 2015, "Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study"], ["N LaRusso", 2015, "P1184: Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with \u2026"], ["Jacob George", 2015, "Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years"], ["Aurelie Plessier", 2015, "Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis"], ["Peter JM Valk", 2015, "Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis"], ["Isabel Chu", 2015, "Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis"], ["Harry J Janssen", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Kenneth J Rothschild", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Mark J Lim", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Patrick SC Leung", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Donald B Bloch", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Jinjun Wang", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Amany Awad", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Chen\u2010Yen Yang", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Piotr Milkiewicz", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Iannis E Adamopoulos", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Catalina Coltescu", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["M Eric Gershwin", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Heather P Ostendorff", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Gary L Norman", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Zakera Shums", 2015, "Anti\u2010kelch\u2010like 12 and anti\u2010hexokinase 1: novel autoantibodies in primary biliary cirrhosis"], ["Fibo JW ten Kate", 2015, "CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses"], ["Gretchen N de Graav", 2015, "CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses"], ["Carla C Baan", 2015, "CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses"], ["Jean-Fran\u00e7ois Dufour", 2015, "Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily \u2026"], ["Christos Papaioannou", 2015, "Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir"], ["MJ Fritzler", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["GG Kaplan", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["GL Norman", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["LM Stinton", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["C Bentow", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["M Mahler", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["P Milkiewicz", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["Bj\u00f6rn Lindkvist", 2015, "PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)"], ["Mohamad H Imam", 2015, "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis"], ["V Isakov", 2015, "H\u00e9patite B"], ["AW LeMair", 2015, "H\u00e9patite B"], ["SK Ono", 2015, "H\u00e9patite B"], ["JJ Gonvers", 2015, "H\u00e9patite B"], ["AG Khan", 2015, "H\u00e9patite B"], ["CT Yeh", 2015, "H\u00e9patite B"], ["Z Abbas", 2015, "H\u00e9patite B"], ["J Sollano", 2015, "H\u00e9patite B"], ["MF Yuen", 2015, "H\u00e9patite B"], ["SG Lim", 2015, "H\u00e9patite B"], ["A Elewaut", 2015, "H\u00e9patite B"], ["CW Spearman", 2015, "H\u00e9patite B"], ["Irene Franceschet", 2015, "Incidence and Impact of Decompensating Events in Primary Biliary Cirrhosis: Results of an International Follow Up Study of 3030 Patients"], ["Llorenc Caballeria", 2015, "Incidence and Impact of Decompensating Events in Primary Biliary Cirrhosis: Results of an International Follow Up Study of 3030 Patients"], ["H Ye", 2015, "Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy"], ["Ashley S Brown", 2015, "Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy"], ["David J Mutimer", 2015, "Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy"], ["Y Oo", 2015, "Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: results from a large European multi \u2026"], ["D Mutimer", 2015, "Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: results from a large European multi \u2026"], ["A Brown", 2015, "Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: results from a large European multi \u2026"], ["Virgil Surveillance Study Group", 2015, "Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: results from a large European multi \u2026"], ["Hans Orlent", 2015, "High-dose (peg) interferon therapy in treatment-naive, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C"], ["Eric A Steegers", 2015, "[5-OR]: Transient elastography (TE) of the liver as a new diagnostic tool to discriminate between HELLP syndrome and acute fatty liver of pregnancy (AFLP)?"], ["Robbert J de Knegt", 2015, "[5-OR]: Transient elastography (TE) of the liver as a new diagnostic tool to discriminate between HELLP syndrome and acute fatty liver of pregnancy (AFLP)?"], ["Johannes Duvekot", 2015, "[5-OR]: Transient elastography (TE) of the liver as a new diagnostic tool to discriminate between HELLP syndrome and acute fatty liver of pregnancy (AFLP)?"], ["Rob De Man", 2015, "[5-OR]: Transient elastography (TE) of the liver as a new diagnostic tool to discriminate between HELLP syndrome and acute fatty liver of pregnancy (AFLP)?"], ["Leonard Neven", 2015, "[5-OR]: Transient elastography (TE) of the liver as a new diagnostic tool to discriminate between HELLP syndrome and acute fatty liver of pregnancy (AFLP)?"], ["Claudia Verveer", 2015, "[5-OR]: Transient elastography (TE) of the liver as a new diagnostic tool to discriminate between HELLP syndrome and acute fatty liver of pregnancy (AFLP)?"], ["Mark Swain", 2015, "Time to make the change from \u2018primary biliary cirrhosis\u2019 to \u2018primary biliary cholangitis\u2019"], ["Catherine Vincent", 2015, "Time to make the change from \u2018primary biliary cirrhosis\u2019 to \u2018primary biliary cholangitis\u2019"], ["Zwier MA Groothuismink", 2015, "ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection"], ["Robert Roomer", 2015, "ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection"], ["Terri Mathisen", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Chong-Gee Teo", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Susan Strom", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Stacey Minshall", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Nezam Afdhal", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Cassandra Rodd", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Lili T Punkova", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Yury Khudyakov", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Ashley Ungermann", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Jenny Heathcoate", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Jama M Darling", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Peter Poerzgen", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Debra L King", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Anna Suk-Fong Lok", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Johanna Han", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Emma Olson", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Mohamed Hassan", 2015, "Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype"], ["Fiona McPhee", 2015, "IFN\u2010\u03bb\u2010mediated IL\u201012 production in macrophages induces IFN\u2010\u03b3 production in human NK cells"], ["Bi\u2010Sheng Liu", 2015, "IFN\u2010\u03bb\u2010mediated IL\u201012 production in macrophages induces IFN\u2010\u03b3 production in human NK cells"], ["Rik A de Groen", 2015, "IFN\u2010\u03bb\u2010mediated IL\u201012 production in macrophages induces IFN\u2010\u03b3 production in human NK cells"], ["Jacques Friborg", 2015, "IFN\u2010\u03bb\u2010mediated IL\u201012 production in macrophages induces IFN\u2010\u03b3 production in human NK cells"]]}